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Solid lipid–polymer hybrid nanoparticles (SLPN) are nanocarriers made from a
combination of polymers and lipids. By integrating the advantages of biocompatible lipid-based
nanoparticles and gastrointestinal (GI)-stable polymeric nanoparticles, SLPN are the ideal
delivery system for delivering lipophilic compounds orally. In this project, two novel preparation
strategies were proposed to fabricate GI-stable SLPN: 1) Bovine serum albumin (BSA) and
dextran were first conjugated through Maillard reaction and the conjugates were exploited as
macromolecular emulsifier and surface coating layer to prepare SLPN by a solvent diffusion and
sonication method. In this approach, the multilayer structure was formed by self-assembly of BSAdextran micelles to envelope solid lipid via a pH- and heating-induced facile process with
simultaneous surface deposition of pectin; 2) Dextran was first oxidized and functionalized with
more surface aldehyde groups, and then the SLPN was fabricated through in situ conjugation
between oxidized dextran and BSA-emulsified solid lipid. Both types of SLPN were applied to
encapsulate lipophilic bioactive compounds, including curcumin and astaxanthin (ASTN). The
major objectives of this dissertation were to 1) systematically study the fabrication parameters in
two preparation strategies to prepare SLPN; 2) comprehensively characterize the structural and
colloidal properties of as-prepared two types of SLPN; 3) explore and compare the encapsulation
and delivery applications of SLPN for lipophilic bioactive compounds, including curcumin and
ASTN. In summary, the surface-functionalized SLPN could significantly improve the
physicochemical properties of lipid nanoparticles and expand their potential as oral delivery
systems for lipophilic bioactive compounds.
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Chapter 1 Introduction
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Many lipophilic bioactive compounds, such as curcumin and astaxanthin (ASTN), have
been proved to possess potent antioxidant abilities [1, 2]. However, many factors, including poor
water-solubility, chemical instability, and low oral bioavailability, have limited its practical
applications in functional food to improve human health [3, 4]. Consequently, there has been
growing interest in developing various kinds of colloid-based delivery systems to overcome these
challenges [5-7].
When designing nanoscale delivery systems to encapsulate lipophilic bioactive
compounds for oral delivery, there are several factors need to be taken into consideration. First
of all, these nanoscale delivery systems should be fabricated with generally recognized as safe
(GRAS) ingredients. GRAS is an US Food and Drug Administration (FDA) description that a
chemical or substance is safe under the conditions of its intended use. One promising method is
to formulate nanoscale delivery systems with naturally-occurring biomaterials, particularly from
food sources [4, 5]. Lipid, protein, and polysaccharide are three major natural biomaterials in food
that have been extensively studied to fabricate nanoscale oral delivery systems for nutrients. Each
natural biomaterial-based delivery system has their unique characteristics when compared to
others. For example, proteins have good affinity to bioactive compounds due to its amphiphilic
nature, however, they have poor thermal stability and are sensitive to acidic pH, as well as
digestive enzymes, making them unsuitable for oral delivery. Polysaccharides are resistant to
digestive enzymes and acidic condition, while their high hydrophilicity compromise their capability
to encapsulate lipophilic compounds. In our case, lipid-based delivery systems are ideal selection
in terms of accommodating lipophilic bioactive compounds, as their lipid regions could provide a
strong hydrophobic environment for encapsulation. Among all the lipid-based nanoscale delivery
system, solid lipid nanoparticles (SLN) are the most studied lipid-based formulation due to their
simple preparation process, high loading capacity for lipophilic compounds, and slow release rate
[6]. Generally, SLN are prepared by emulsifying physiological lipids (e.g. mono-, di-, and
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triglycerides) or saturated fatty acids (e.g. stearic acid, palmitic acid) at 5-10 °C higher than their
respective melting point, followed by recrystallization at a lower temperature to solidify the inner
lipid droplets stabilized by synthetic or natural surfactants/emulsifiers [8]. For realizing practical
applications of prepared SLN in food industry, it is necessary to use natural emulsifiers instead of
synthetic surfactants in SLN formulations. With this in mind, proteins are usually selected due to
their amphiphilic nature, as well as their good biocompatibility. In fact, proteins such as casein
and bovine serum albumin (BSA) are used for their emulsification ability and extensively utilized
to prepare traditional emulsion in the food industry [9-11].
Furthermore, the GI tract is a biological diverse and complicated system, which mainly
includes oral cavity, esophagus, stomach, small intestine, and large intestine. Each partition of
the GI tract maintains its own distinctive pH level and enzymatic variety and activity. Therefore,
oral administration of protein-emulsified SLN is often compromised by many factors such as
possibility of degradation in the harsh pH/enzymatic conditions of the GI tract [12]. Proteins may
precipitate under low pH in the stomach and thus lose their emulsification ability since they are
sensitive to fluctuation of pH value and ionic strength. Moreover, lipid molecules will form large
aggregates under acidic environment due to protonation of carboxyl groups, and thus SLN lose
their nanostructure after entering the stomach. In the last decade, increasing interest has been
drawn to apply surface modifications to SLN with biopolymers such as polysaccharides to form
hybrid nanoparticles, which is considered to be an effective method to significantly improve GI
stability of SLN [13-15]. Polysaccharides possess superior properties over other synthetic polymer
in terms of biocompatibility. Coating SLN with digestion-resistant polysaccharides (e.g. pectin,
alginate) have been investigated in many previous studies [14, 16, 17]. However, due to the weak
association (e.g. electrostatic force) between those polysaccharides with solid lipids and
emulsifiers, such surface modifications are usually accompanied by the use of synthetic crosslinkers (i.e. glutaraldehyde (GA)), which however might pose toxicity problems for further
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applications in the food industry. Thus, it is critical to develop a GI-stable and naturally-derived
lipid-based hybrid formulation without potential toxic cross-linkers.
The main objective of this project is to develop safe, effective, and GI-stable oral delivery
system for lipophilic bioactive compounds using all-natural biomaterials and a simple surface
modification process to improve its bioavailability. Due to its low bioavailability caused by high
hydrophobicity, strategies for effective delivery of lipophilic bioactive compounds are needed to
maximize its health benefits. Our central hypothesis is that encapsulation of lipophilic bioactive
compounds in GI-stable solid lipid–polymer hybrid nanoparticles (SLPN) prepared using natural
ingredients will increase their bioavailability.

4

Chapter 2 Literature Review

Part of contents, including texts and figures, has been published in Nanoscale, 2019, 11, 1104811063. This chapter was adapted and reprinted with permission from Royal Society of
Chemistry.
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2.1. Lipophilic bioactive compounds and their low oral bioavailability
There has been a growing interest of investigating the pivotal link between diet and human
health since the end of last centenary. This has led to the development of a new category of foods,
the so-called functional foods [18]. Functional foods contain a variety of components and nutrients
that affect a range of body functions related to a state of well-being and health and/or reduce the
risk of a disease [19]. Food components with health benefits in such functional foods are often
known as “bioactive compounds” and these compounds typically occur in small quantities in
certain foods. Many lipophilic bioactive compounds, such as curcumin and ASTN, are well known
for their therapeutic benefits in the aging process and various diseases because of their potent
antioxidant abilities [20]. Previous studies have demonstrated that the primary mechanism of
action of this antioxidant activity appears to be the their ability to quench excited sensitizer
molecules as well as active oxygen species [21]. Curcumin is a pigment isolated from the plant
Curcuma longa (also known as turmeric) and it is a diarylheptanoid, belonging to the group of
curcuminoids, which are natural phenols responsible for turmeric’s yellow color. Turmeric is
commonly cultivated in Asian countries, mostly in India and China and it has a very long history
of medicinal use. Previous studies have proved that curcumin modulates numerous molecular
targets and exerts antioxidant, anti-inflammatory, anticancer, and neuroprotective activities [22].
ASTN was originally isolated from lobster by Kuhn et al. in 1930s [23] and it is a pigment that
belongs to the family of the xanthophylls, which is the oxygenated derivatives of carotenoids.
ASTN can be found in nature primarily in marine organisms, such as microalgae, salmon, trout,
krill, shrimp, crayfish, and crustaceans, in which the main role of ASTN is to provide the desirable
reddish-orange color in these organisms as they do not have access to natural sources of
carotenoids. Among the abovementioned sources, the green microalga Haematococcus pluvialis
is considered the richest source of ASTN [24]. In addition to marine organisms, ASTN can be
found in feathers of birds, such as quail, flamingo, and storks. As a member of the carotenoid
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family, ASTN shows strong antioxidant properties, and exhibits strongest antioxidant ability
among carotenoids. Naguib et al. compared antioxidant activities of ASTN and related
carotenoids, including lycopene, α-carotene, β-carotene, and lutein, by a fluorometric assay and
found ASTN exhibited the strongest antioxidant activity of the selected carotenoids tested [25].
Furthermore, ASTN showed stronger antioxidant activity compared to some other antioxidant
vitamins like vitamin E and vitamin C, respectively 14 and 65 times [26]. However, many factors,
including poor water-solubility, chemical instability, and low oral bioavailability, have limited its
practical applications in functional food to improve human health [2, 3]. Consequently, there has
been growing interest in developing various kinds of colloid-based delivery systems to overcome
these challenges [4-6].

2.2. General consideration of colloidal delivery systems of lipophilic bioactive compounds
When considering a nanoscale oral delivery for bioactive compounds, the nanoparticles
should be prepared with GRAS ingredients using reliable fabrication procedures. Currently, the
nanoparticles found in food may consist of inorganic (i.e. silver, titanium dioxide, zinc oxide)
and/or organic components (i.e. lipids, proteins, polysaccharides). However, the inorganic
nanoparticles are often associated with potential toxicity due to their active chemical reactivity.
For example, silver nanoparticles, as well as organic-coated silver nanoparticles, are able to
generate reactive oxygen species (ROS) thus promoting oxidative stress, resulting in damage to
cell membrane, organelles, and the nucleus [27, 28]. In contrast, due to biodegradable and
biocompatible nature of lipids, proteins, and polysaccharides, the organic nanoparticles are
considered less toxic than inorganic ones, making them ideal oral nanoscale carrier for lipophilic
bioactive compounds.
Moreover, different biomaterials exhibited different encapsulation capability for lipophilic
compounds. For example, lipid-based nanoparticles show excellent affinity to lipophilic
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compounds, while polysaccharide-based nanoparticles are unable to encapsulate hydrophobic
compounds unless the hydrophilic polymeric chains of polysaccharide are grafted with
hydrophobic segments [29], making the encapsulation procedure of lipophilic bioactive
compounds much more expensive and complicated. Due to the amphiphilic nature of protein,
protein-based nanoparticles are capable of encapsulating either hydrophobic or hydrophilic
bioactive compounds.
Also, composition of nanoparticles plays a critical role in determining their gastrointestinal
(GI) fate. Lipid-, protein- and polysaccharide-based nanoparticles may show considerable
difference in behavior during transportation in the GI tract, they may dissolve, precipitate,
aggregate, or be digested in the stomach, small intestine, or colon depending on their composition
and structures. For example, protein-based and lipid-based nanoparticles are extremely sensitive
to pH and ionic strength alternation and digestive enzymes in GI tract. While, polysaccharidebased nanoparticles are resistant to digestive enzymes and acidic condition. Further detailed
information of natural biomaterial-based colloidal delivery systems will be provided in the following
section.

2.3. Natural biomaterial-based colloidal delivery systems for oral delivery
In recent years, there has been growing interest in the development of colloid-based
delivery systems to encapsulate, protect, and release lipophilic bioactive compounds in the food
industry [30, 31]. Encapsulation of lipophilic bioactive compounds in nanoscale delivery vehicles
offers multiple advantages including controlled and sustained release, improved bioavailability
and target delivery [5-7, 32, 33] when compared with conventional administration.
Lipid, protein, and polysaccharide are three major natural biomaterials that have attracted
increasing attention to fabricate nanoscale oral delivery system for nutrients during recent years.
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Lipid-, protein-, and polysaccharide-based nanoscale delivery system could be assembled using
various bottom-up and top-down techniques, such as self-assembly and emulsification method,
respectively. Each natural biomaterial-based delivery system has their unique properties,
advantages and disadvantages when used as oral delivery systems for lipophilic compounds and
they will be discussed in the following sections.

2.3.1. Protein-based colloidal delivery system
Protein-based colloidal carriers are nontoxic, biodegradable, and easily metabolized and
possess good biocompatibility. Protein-based nanocarriers can be degraded by the action of
enzymes present inside the human body. In addition, protein nanoparticles have been found to
elicit a weak or negligible immune response. Protein-based nanoparticles could be precisely
designed for use in many formulations and almost any ingredients can be encapsulated, either
hydrophobic or hydrophilic, due to amphiphilic nature of protein. Various strategies and
techniques, including coacervation/desolvation, self-assembly, cross-linking, etc., have been
successfully

applied

for

the

fabrication

of

protein-based

nanoparticles

[34].

Coacervation/desolvation is based on the differential solubility of proteins in solvents as a function
of solvent polarity, pH, ionic strength, and presence of electrolytes. The principle of this method
is to reduce the solubility of an aqueous protein solution by using a desolvating agent such as
ethanol or acetone, resulting in phase separation and precipitation of protein nanoprecipitates.
The obtained protein nanoprecipitates are then redispersed in water under sonication to form
protein nanoparticles with addition of cross-linkers. Proteins like soy protein [35], whey protein
[36], BSA [37], human serum albumin (HSA) [38, 39], gelatin [40], and legumin [41] can be
successfully prepared into nanoparticles by coacervation. Protein micelles can be formed
spontaneously when the individual protein chains are directly dissolved in aqueous solution above
a critical micelle concentration (CMC) and critical micelle temperature (CMT) [42]. A variety of
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naturally occurring proteins such as casein [43, 44] and BSA [45] can self-assemble into
nanoparticles. After preparation of protein nanoparticles, the particles are often cross-linked by
cross-linkers (i.e. chemical, ionic) to further solidify nanoparticulate structure. Lysine residues of
the protein are generally involved in such cross-linking procedure. Generally, cross-linkers are
essential for protein-based nanoparticles preparation to increase their stability. Langer et al.,
prepared HSA nanoparticles by a desolvation technique and found that non-cross-linked albumin
nanoparticles tend to merge to form aggregations unless they are chemically cross-linked [39].
However, for oral delivery applications, it is essential to completely remove the free cross-linkers
due to their toxicity [46]. By applying the encapsulation technique using protein-based
nanoparticles, the stability and solubility of encapsulated lipophilic compounds is significantly
improved. On the other hand, the protein-based vehicles themselves are extremely sensitive to
pH and ionic strength alternation and digestive enzymes in GI condition when administering orally,
making protein-based nanoparticles not the optimal choice for oral delivery unless modifications
or functionalization are applied.

2.3.2. Polysaccharide-based colloidal delivery system
Unlike proteins, polysaccharides present outstanding stability in GI environment, making
them appropriate biomaterials for oral delivery. Polysaccharides, which are ubiquitous
biopolymers made up of repeated mono- or di-saccharides linked via glycosidic bonds, hold great
promise as drug carriers because of their unique physicochemical properties; they can be neutral,
positively (polycationic), or negatively (polyanionic) charged, they can have a linear or branched
molecular architecture, and their molecular weight can range anywhere from a few hundred to
several thousand Daltons [47]. In general, polysaccharide-based nanoparticles are prepared
mainly

by

two

mechanisms,

namely

cross-linking

and

polyelectrolyte

complexation.

Polysaccharide-based nanoparticles can be fabricated by inter- or intra- molecular cross-linking
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and/or complexation of polysaccharide chains, where the bonds can be either ionic or covalent.
The covalent cross-linking method involves the introduction of covalent bonds between the
polysaccharide chains. Such method usually requires complex conjugation chemistry and specific
reaction conditions. Many previous studies reported that chitosan can be covalently cross-linked
by formaldehyde or glutaraldehyde to form nanoparticles [48-50]. Chitosan contains large
amounts of free amino groups and hydroxyl, which are capable of reacting with aldehyde groups
under weak acidic conditions. Unfortunately, the small molecule chemical cross-linkers, usually
formaldehyde or glutaraldehyde, often exhibit toxic effect on cell viability, thus the covalent crosslinking method are often avoided for preparation of nanoparticles [51]. In recent years, covalent
cross-linking becomes promising along with the employ of biocompatible cross-linkers such as
succinic acid, malic acid, and citric acid together with some condensation agents (i.e. 1-ethyl-3(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)) [52, 53]. Besides, Polysaccharidebased nanoparticles can be prepared by ionically cross-linking polyelectrolytes with multivalent
ions of opposite charges. Compared with covalent cross-linking method, the ionic cross-linking
method is more facile. However, such method is limited to charged polysaccharides. In contrast,
the covalent cross-linking method can be applied to neutral polysaccharide. The most widely
studied nanoparticles prepared by this method are chitosan nanoparticles cross-linked with
tripolyphosphate (TPP) [54]. Besides, nanoparticles based on alginate can be prepared by crosslinking with calcium ions [55]. Although ionic cross-linking is usually considered as superior
preparation method to covalent cross-linking due to mild preparation conditions and simple
procedures, the ionically cross-linked nanoparticles are less stable than covalently cross-linked
ones, due to differences in bond strength. Polysaccharides with a polyelectrolyte character can
form polyelectrolyte complexation (PEC) with oppositely charged polymers through intermolecular
electrostatic interaction. For example, positively charged chitosan can form PEC with negatively
charged alginate [56], cellulose [57], and dextran [58, 59] under certain conditions. However, high
hydrophilicity nature of polysaccharide-based nanoparticles restricts their capability to
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encapsulate lipophilic compounds. In recent years, a new method for preparation of
polysaccharide-based nanoparticles, self-assembly od amphiphilic polysaccharide derivative
modified with hydrophobic moieties, have been developed [60]. By grafting hydrophobic moieties
to the polysaccharide backbone, amphiphilic polysaccharide derivatives can self-assemble into
nanoparticles with multiple hydrophobic inner cores covered by a hydrophilic polysaccharide shell
under aqueous conditions. The resultant hydrophobic cores have been exploited as reservoirs for
the delivery of several poorly water-soluble drugs [61, 62]. However, complicated chemical
reactions and organic solvents are often involved in such modification. Excess chemical
modification may also result in the loss of the physicochemical or biological characteristics of the
parent polysaccharides [63].

2.3.3. Lipid-based colloidal delivery system
Compared

to

protein

and

polysaccharide-based

delivery

system,

lipid-based

nanoparticles are the ideal system for oral delivery of lipophilic compounds, as the lipid region
could provide strong hydrophobic environment for encapsulated hydrophobic compounds. In
addition, lipid-based nanoparticles could improve GI absorption and oral bioavailability of
encapsulated cargos, especially lipophilic compounds. The lipids used in lipid-based
nanoparticles are generally physiological lipids, including mono-, di- and triglycerides, fats, waxes,
sterols, and phospholipids. Thus, lipid-based nanoparticles are characterized to be non-toxic,
biocompatible and completely biodegradable. When referring to lipid-based nanoscale delivery
systems, it includes liposome, SLN, nanoemulsions, NLC, etc. Each lipid-based colloidal system
has its unique properties, advantages and disadvantages as oral delivery system. Liposomes (Fig.
2.1A) are vesicular structures composed of amphiphilic molecules, such as phospholipids. The
formation mechanism of liposomes is based on the interaction between amphiphilic compounds,
mainly phospholipids, and water molecules. During liposomes formation process, the polar heads
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of phospholipids are subjected to the aqueous phases of the inner and outer media, and the
hydrophobic tails are associated into the bilayer and spherical core shell structures can be formed
[64]. Nanoemulsions (Fig. 2.1B) are dispersions of two immiscible liquids (water and oil) stabilized
by a surfactant/emulsifier. Nanoemulsions can be oil-in-water (O/W) emulsions as the oil phase
is dispersed into the water continuous phase, but can also be water-in-oil (W/O) emulsions when
the water phase is dispersed into the oil continuous phase. SLN (Fig. 2.1C) are nanostructures
composed of solid lipids (solid in room temperature) and surfactant/emulsifier. Compared with
liposomes and nanoemulsions, SLN have several distinct advantages, including high
encapsulation efficiency, high flexibility in controlling the release profile, and slower degradation
rate in vivo. NLC (Fig. 2.1D) share similar structures with SLN, but the solid lipid core is replaced
by a mixture of solid and liquid lipid. By partially replacing the solid lipid matrix by liquid oil, the
encapsulation capacity of nanoparticles for payloads is enhanced and expulsion phenomenon
during storage is limited by preventing the formation of perfect crystals in lipid matrix [65, 66].
However, the storage stability of NLC is not good as SLN due to the liquid oil part in lipid matrix.
The methods used to produce lipid-based nanoparticles can be divided into the mechanical (i.e.
homogenization, microfluidization, ultrasonication) and non-mechanical (i.e. solvent diffusion,
phase inversion temperature, spontaneous emulsification) techniques. In mechanical methods,
large disruptive forces are provided to break up the lipid and water phases and lead to formation
of oil droplets by the use of mechanical devices such as high-pressure homogenizers,
microfluidizers, and ultrasonicators. However, in non-mechanical methods, high energy input is
not required during preparation of lipid nanoparticles [67-70]. Non-mechanical methods depend
on the spontaneous formation of nanoparticles in o/w surfactant system when their temperature,
composition, or solubility in changed [71-75]. All lipid-based nanoparticles can be prepared
through both approaches. For example, SLN could be either prepared by high-pressure
homogenization [76] or emulsification-diffusion technique [75]. Among all the lipid-based
nanoscale delivery system, SLN are the most studied lipid-based formulation due to their simple
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preparation process, high loading capacity for lipophilic compounds, good storage stability and
slow release rate. Still, when utilizing for oral delivery, lipid-based nanoparticles are unstable at
stomach condition (low pH) due to protonation of carboxyl groups.

2.3.4. Development of lipid-based hybrid nanoparticles
Due to disadvantages of each natural biomaterial-based oral delivery system,
development of hybrid nanoparticles or complex nanoparticles which combine all the valuable
features of different delivery system is critically needed. In recent years, protein/polysaccharide
hybrid nanoparticles have been extensively studied [77, 78]. Generally, the mechanism by which
protein and polysaccharide assembly into hybrid nanoparticles is based on electrostatic and
hydrophobic interactions under mild conditions and specific pH. The pH is usually adjusted to
allow protein and polysaccharide molecules carry opposite surface charge to simultaneously
assemble into nanoparticles. Many protein/polysaccharide hybrid nanoparticles have been
successfully fabricated (e.g. sodium caseinate (NaCas)-pectin nanoparticles [79], β-lactoglobulinpectin nanoparticles [80, 81]) and applied to encapsulate a variety of bioactive compounds, such
as vitamin D3 [82] and rutin [79]. Due to polyelectrolyte interactions protein/polysaccharide hybrid
nanoparticles, the stability of prepared nanoparticles will be strongly influenced by pH, ionic
strength, charge density and the concentration of the biopolymers. Thus, these hybrid
nanoparticles are susceptible to pH change and digestive enzymes in GI tract, resulting in poor
stability and fast release of encapsulated cargos. While previous studies have demonstrated that
the stability of protein/polysaccharide hybrid nanoparticles in GI tract can be significantly improved
by creating covalent bond between protein and polysaccharide using chemical cross-linkers [83,
84].
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As mentioned in previous sections, although lipid-based nanoscale delivery systems,
especially SLN, are ideal candidates for encapsulation and delivery lipophilic bioactive
compounds orally, the poor stability in GI tract compromises their applicability as oral delivery
systems. Nevertheless, in a recent study conducted by Ramalingam et al., they successfully
improved the GI stability of SLN by applying polysaccharide coating (i.e. N-trimethyl chitosan) on
SLN [85]. However, due to the heavy use of organic solvents and synthetic surfactants during
preparation of SLN, such lipid-polysaccharide hybrid nanoparticles may not be suitable as oral
delivery system for lipophilic bioactive compounds. Therefore, the development of safe and
effective lipid-based hybrid oral delivery system for lipophilic bioactive compounds is critically
needed.

2.4. In vivo biological fate of lipid-based nanoparticles
Lipid-based nanoparticles have been widely used to encapsulate, protect, and deliver
lipophilic drugs/nutrients. Although existing studies have demonstrated that lipid-based
nanoparticles could improve the oral bioavailability of encapsulated cargos, the understanding of
their in vivo digestion and absorption is an impediment to their further development and practical
application. Taking together plenty of studies related to this topic, the in vivo biological fate of
ingested lipid-based nanoparticles and the underlying mechanisms and pathways can be
classified into two categories based on whether or not the lipid-based nanoparticles are digestible
in the GI tract.
For digestible lipid-based nanoparticles (Fig. 2.2), first of all, the ingested lipid-based
nanoparticles will be subjected to digestion by lipases and hydrolysis throughout the GI tract, and
the lipid digestion products containing fatty acids and monoglycerides will be transformed into
mixed micelles, together with encapsulated cargos, bile salts and phospholipids. After absorption
by enterocytes, the lipid digestion products and encapsulated cargos enter the circulation through
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either the portal vein or lymphatic system, depending on the structure of lipids in the lipid-based
nanoparticles formulation and hydrophobicity of encapsulated cargos.
In contrast, for indigestible lipid-based nanoparticles, they can remain integral and
possibly penetrate through the mucus layer to come in contact with epithelia (Fig. 2.3). After
penetration, these lipid-based nanoparticles can be transported through the tight junction, or taken
up by enterocytes or transported by Microfold (M) cells, to enter the circulation. Even though the
transportation mechanisms of integral lipid-based nanoparticles through intestinal epithelia have
been well studied using in vitro models (mainly Caco-2 cell monolayers and Caco-2/HT29/Raji
cell co-culture), such in vitro results were only parts of the whole picture. In recent years, several
animal studies have revealed that most of the digestible lipid-based nanoparticles were degraded
in the GI tract via lipolysis and hydrolysis and only a small fraction of lipid-based nanoparticles
that survived the GI environment were absorbed by enterocytes and/or M cells. In general, the
lipolysis and subsequent stimulation of micellular species production seem to be the major
mechanisms for enhancing absorption of lipophilic compounds delivered by lipid-based
nanoparticles. However, the lipid-based nanoparticles formulation used in many studies is way
too simple to ensure the integrality and stability of lipid-based nanoparticles under physiological
GI conditions before the absorption by epithelia could occur. Therefore, the transportation of
indigestible lipid-based nanoparticles across the intestinal epithelium still requires experimental
verification, especially for GI-stable lipid-based nanoparticles with a complicated structure (e.g.
lipid-polysaccharide hybrid nanoparticles).
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2.5. Figures and tables
Figure 2.1 Structure of liposome (A), nanoemulsion (B), solid lipid nanoparticles (SLN) (C), and
nanostructured lipid carriers (NLC) (D).
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Figure 2.2 Transportation of digestible lipid nanoparticles and encapsulated cargos to systemic
circulation. FA: fatty acid, MG: monoglyceride, TG: triglyceride, ER: the endoplasmic reticulum.
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Figure 2.3 Schematic of indigestible lipid nanoparticles transport across the intestinal
epithelium.
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Chapter 3 Study 1
Solid lipid nanoparticles coated with crosslinked polymeric double layer for oral delivery

This study has been published in Colloids and Surfaces B: Biointerface, 2016, 148, 1-11. This
chapter was adapted and reprinted with permission from Elsevier.
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3.1. Background
In the last decade, increasing interest has been drawn to design surface-modified SLN
with various coatings, such as polymers [86], poly (ethylene glycol) (PEG) [87], and small
molecular surfactants (ionic and non-ionic) [88]. Such surface modifications are considered to
confer new physicochemical properties to SLN and have been shown to bring enhanced
functionalities. For instance, chitosan coated SLN demonstrated great potential to deliver both
hydrophobic [89-91] and hydrophilic drugs, including peptides [92, 93], insulin [94, 95], and
quercetin [86, 96], by enhancing the encapsulation efficiency and intestinal absorption as well as
avoiding phagocytosis by mononuclear phagocytic system after intestinal uptake. On the other
hand, the pharmacokinetic and tissue distribution study of PEG-coated SLN indicated that the
stealth effects of PEG significantly prolonged blood circulation time and topical concentration in
brain when administered intravenous injection [97]. Furthermore, different synthetic surfactants
may result in different physicochemical properties and loading efficacy of coated SLN [98].
Nevertheless, there are often potential toxicities associated with synthetic coatings or emulsifiers
used in the preparation of SLN [99].
Coating SLN with natural biopolymers (carbohydrates and proteins) to prepare SLPN have
been rarely explored so far, which is probably due to the weak association between natural
biopolymers and solid lipids at the colloidal interface. NaCas and pectin are the natural
biopolymers from food sources, i.e. major protein fraction from milk and polysaccharide from plant
cells, respectively. Owing to its amphiphilic property, NaCas is well known for its emulsification
property by adsorbing to oil/water interface [100], while pectin is widely studied for its capability
to stabilize NaCas particles at acidic conditions by forming complex particles [101].The
complexation between NaCas and pectin is due to the facile electro-deposition process induced
by adjusting pH and subsequent thermal treatment, and the resultant complex particles can be
either nanoscale [79] or microscale [102], depending upon the concentration of two biopolymers.
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In this study, we aimed to explore the drug/nutrient delivery potentials of SLPN with
biopolymeric double layer (DL) coatings, consisting of NaCas and pectin, with curcumin studied
as a model compound. To further improve the encapsulation efficiency, physical stability and
sustained release in simulated GI conditions, the polymeric coatings (NaCas and pectin layers)
were chemically cross-linked by different cross-linkers, i.e. glutaraldehyde (GA) and 1-Ethyl-3-(3dimethylaminopropyl) carbodiimide/N-Hydroxysuccinimide (EDC/NHS) and the effects of crosslinking were compressively investigated herein.

3.2. Experimental design
3.2.1. Preparation of single-layer and double-layer solid lipid nanoparticles
Biopolymeric single-layer (SL) curcumin-loaded SLPN were prepared by combining the
solvent-diffusion and hot homogenization technique, as detailed elsewhere [90]. Briefly, 20 mg of
ATO 888 was completely dissolved in the organic phase (preheated to 80 °C in a water bath),
consisting of equal volume of acetone (0.5 mL) and ethanol (0.5 mL), to give a final lipid
concentration of 20 mg/mL. To this organic phase, different amount (80, 200, or 400 μL) of
curcumin solution (2.5 mg/mL in ethanol) was added at the same temperature. The obtained
solution was then sheared into 20 mL of aqueous phase containing NaCas at 1.2 mg/mL under
homogenization at 13,5000 rpm for 3 min using a dispenser (IKA T18 digital ULTRA-TURRAX®,
Germany), followed by 3 min sonication using a sonicator (Misonix Sonicator® 3000, USA). Then
the sample was cooled down in ice bath with magnetic stirring at 400 rpm until reaching room
temperature. To coat NaCas-emulsified lipid nanoparticles with pectin and generate biopolymeric
double-layer (DL) SLPN, pectin, which was pre-hydrated overnight and pH adjusted to 6.8, was
added into the aqueous phase. To induce electro-deposition of pectin onto the surface of NaCas
layer, the mixture was then adjusted to pH 5 before heating at 80 °C for 30 min to reinforce the
coating structure. After that, samples were rapidly cooled down to room temperature in ice bath
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to solidify SLPN. The final sample was then filtrated through a 0.45 μm syringe filter and
centrifuged (8,000 × g, 30 min) to remove insoluble free curcumin.

3.2.2. Cross-linking of polymeric coatings
The prepared DL SLPN were cross-linked with two different cross-linkers: GA and
EDC/NHS. Briefly, 0.25 mL of GA (25%) or EDC/NHS (1 mg/mL, EDC: NHS = 1:1, w/w) solution
was added into 5 mL sample to initiate chemical cross-linking process under continuous stirring
for 1 h. After that, the excess cross-linker and unloaded free curcumin were removed through
dialysis (10 kDa molecular cutoff) for about 12 h, with water changed every 6 h. The obtained
samples were hereafter labelled as G-SLPN (GA cross-linked) and E-SLPN (EDC/NHS crosslinked) and stored in the dark at 4 °C.

3.2.3. Characterization of SLPN
The particle size, polydispersity index (PDI), and zeta potential of SLPN were measured
by Zetasizer Nano ZS at 25 °C (Malvern Instruments Ltd, Worcestershire, UK). Particle size was
determined by dynamic light scattering (DLS) at a scattering angel of 173°. Samples were diluted
10 times with ultrapure water to avoid any effects of multiple scattering. PDI, which is a parameter
to evaluate the size distribution and homogeneity of the nanoparticles in the dispersion, was
recorded together with particle size measurement. Zeta potential was calculated from the
electrophoretic mobility of the sample and used to determine the stability of nanoparticles.
For Fourier transform infrared spectroscopy (FTIR) spectrum analysis, liquid samples
were cast-dried on aluminum pan in fume hood and then stored in a vacuum desiccator to
minimize air exposure. The cast-dried samples were measured by Nicolet iS5 FTIR spectrometer
(Thermo Scientific, Waltham, MA, USA). The infrared spectra were collected from the
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wavenumber of 500–4000 cm−1 at a resolution of 4 cm−1 and analyzed using OMNIC software
version 8.0.
The stability of SLPN in simulated gastric and intestinal conditions was investigated.
Briefly, 1 mL of lipid nanoparticles was added to 9 mL of simulated gastric fluid (SGF, pH 2 or 4,
with 1 mg/mL pepsin) and the mixture was incubated at 37 °C for 2 h. After that, 1 mL of the above
mixture was mixed with 9 mL of simulated intestinal fluid (SIF, pH 7.5 with 10 mg/mL pancreatin)
followed by incubation at 37 °C for 4 h. After each incubation, SLPN were checked for particle
size, PDI and zeta potential as described above.

3.2.4. Determination of encapsulation efficiency
To determine the encapsulation efficiency (EE) of the developed SLPN, the amount of
curcumin entrapped into the nanoparticles was calculated using following equation:

Encapsulation efficiency (EE) =

Mass of curcumin in final product
×100%
Total mass of curcumin

EE was determined by measuring the concentration of curcumin that remained in the final product
after SLPN were filtered (0.45 μm), centrifuged (8000 × g, 30 min) and dialyzed (12 h). The final
concentration of curcumin in SLPN was determined by monitoring the absorbance at 430 nm
using a UV/Vis spectroscopy (Evolution 201, Thermo Scientific, Waltham, MA, USA), with a preestablished curcumin standard curve.

3.2.5. Fluorescence spectroscopy
The fluorescence spectra of NaCas, free curcumin, DL SLPN, G-SLPN and E-SLPN were
recorded using a LS55 Fluorescence Spectrofluorometer (PerkinElmer, Waltham, MA, USA). The
excitation wavelength was 420 nm, and the emission spectra were collected from 450 to 650 nm.
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The step width was set at 0.5 nm for both excitation and emission. The SLPN samples were
diluted to proper concentrations using ultrapure water to reach the instrument sensitivity range.
For free curcumin, it was dissolved at 2.5 mg/mL in ethanol and then diluted with ultrapure water
to the same final concentration as in the SLPN samples. NaCas solution was prepared and diluted
with ultrapure water to the identical final concentration as in the SLPN samples.

3.2.6. ABTS radical scavenging assay
ABTS radical scavenging activity was measured as previously described with some
modifications [103]. First, 1.0 mM 2,2′-Azobis(2-amidinopropane) dihydrochloride (AAPH) and 2.5
mM 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) were mixed in an amber
bottle with 20 mL phosphate buffer solution (PBS, pH 7.4), followed by 30 min reaction under
70 °C in water bath. The obtained mixture was then cooled down, filtered and diluted with PBS to
obtain an absorbance of 0.650 ± 0.020 at 734 nm using a UV/vis spectrophotometer (Evolution
201, Thermo Scientific, Waltham, MA, USA). After that, sample, standard or control (20 μL) was
added to and reacted with the above ABTS+ working solution (230 μL) for 10 min in an automated
plate reader (Synergy H1 M, Thermo Scientific, Waltham, MA, USA) at 25 °C and then the
absorbance was read at 734 nm. A 10, 30, 60, and 100 mg/L of ascorbic acid solutions in PBS
were prepared for standard calibration curve. Samples included free curcumin, DL SLPN, GSLPN, and E-SLPN. Due to poor solubility of free curcumin in aqueous media, free curcumin
control was prepared by first dissolving curcumin in absolute ethanol (2.5 mg/mL) and then
diluting to the appropriate concentration (10, 1, and 0.1 μg/mL) with ultrapure water. All the results
were expressed as mg vitamin C equivalent antioxidant capacity per micro liter sample.

3.2.7. Nano spray drying of SLPN
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Four curcumin-loaded samples, SL-SLN, DL-SLPN, G-SLPN, and E-SLPN, were spray
dried using a Nano Spray Dryer B-90 (Büchi Labortechnik AG, Flawil, Switzerland) with the
following operating conditions: inlet temperature at 100 °C, flow rate at 120 L/min, and mesh size
of 5.5 μm.

3.2.8. Morphological observation
Transmission electron microscopy (TEM) was used to observe the morphology of freshly
prepared G-SLPN and E-SLPN. Samples were first mixed with equal volume of 2%
phosphotungstate (pH adjusted to 7), and then one drop of stained sample was deposited on a
400-mesh copper grid for 10 min. Samples were imaged with a TEM (Tecnai T12, FEI, Hillsboro,
Oregon, USA) at 80 kV. Scanning electron microscopy (SEM) was conducted to visualize the
morphology and shape of spray-dried lipid nanoparticles powders. Powdered samples were
sputter-coated with a thin layer of pure gold before observed under SEM (JSM-6335F, JEOL Ltd.,
Tokyo, Japan).

3.2.9. Differential scanning calorimetry (DSC)
DSC measurements were performed using a DSC Q100® V9.9 Build 303 (TA Instruments,
DE, USA) with standard aluminum sample pans and carried out for the following samples: SLSLN, DL-SLPN, G-SLPN, and E-SLPN, as well as pure ATO 888 as a control. All samples were
dried and stored in a desiccator at room temperature before measurement. Quantities between 5
to10 mg of each sample were weighted. The heating rate was 5 °C/min, with a temperature range
of 22–110 °C and a 50 mL/min nitrogen flow. Indium was used as the reference standard to check
the calibration of the device.
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3.2.10. In vitro controlled release study
The kinetic release profiles of four different samples, free curcumin, DL-SLPN, G-SLPN,
and E-SLPN, were evaluated by the dialysis tubing diffusion technique reported by previous
studies [104, 105]. The release of curcumin from SLPN were performed in SGF (pH = 4) and SIF
(pH = 7.5) with equal volume of ethanol to create a sink condition (50% ethanol) for curcumin [6].
Briefly, 3 mL sample was placed in a cellulose acetate dialysis bag and sealed at both ends. The
dialysis bag was immersed in the receptor bottle containing 60 mL of release medium, which was
gently shaken in a water bath shaker at 100 rpm and maintained at 37 ± 2 °C. The receptor bottle
was covered to prevent the evaporation of dissolution medium. In this in vitro release study, a 2
h SGF stage was followed by a 4 h SIF stage. At both stages, 1 mL of release medium was
withdrawn at predetermined time intervals (every 15 min and 30 min for SGF and SIF,
respectively), and 1 mL of fresh medium was replenished to maintain constant volume. Curcumin
concentration in the withdrawn release medium was spectrophotometrically measured using
standard curves corresponding to release medium (pH = 4 or 7).

3.3. Results and discussions
3.3.1. Synthesis of DL-SLPN
As shown in Fig. 3.1., the particle characteristics were determined before and after pectin
coating process, i.e. pH adjustment and thermal treatment. Before coating process, the particle
size was in the range of 130–140 nm, and the loading concentration of curcumin did not
significantly affect the particle size. However, the PDI, the indicator of size distribution, was
significantly increased from 0.25 to 0.39, as the increase of curcumin loading, explaining the lipid
nanoparticles became heterogeneous when the curcumin loading reached 5%. In contrast, the
particle size of lipid nanoparticles dramatically increased to larger than 300 nm upon coating
process, which may indicate successful adsorption of pectin onto the surface of NaCas-emulsified
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SLN and the difference of particle size was presumably due to the thickness of the pectin coating.
Interestingly, after pectin coating, the PDI was below 0.3 in all samples and was no longer affected
by curcumin loading, suggesting better stability and enhanced encapsulation capability of coated
SLN. Meanwhile, coating process slightly reduced zeta potential of lipid nanoparticles from −50
mV to −45 mV. This slight reduction was owing to the electrostatic interaction between positively
charged amino acid residues of NaCas and carboxyl groups of pectin under coating conditions,
where the pH was closer to the isoelectric point (pI) of NaCas. Similar observations were also
reported in previous studies on the interactions between pectin and proteins at acidic conditions
[106, 107].
Chemical cross-linking between protein and polysaccharide have been well established.
GA and EDC/NHS are the two most commonly used chemical cross-linkers to bridge protein and
polysaccharides. The crosslinking mechanisms of GA and EDC/NHS are illustrated in Fig. 3.2.
GA primarily works as a bifunctional reagent to cross-link amine groups. Although cross-linking
of hydroxyl groups on pectin chain to form acetal linkage has been also reported [108, 109], the
optimal pH is much more acidic (pH ∼ 1.5) than the pH of SLPN samples in our study (pH ∼ 5).
In addition, GA is toxic, the residue of GA in particles after cross-linking was completely removed
(vaporized) during spray-drying process, and thus would not result in any negative effect for later
applications. In contrast, EDC/NHS works as amide-type cross-linker can more efficiently bridge
amino groups of protein and carboxyl groups of polysaccharides [110]. Fig. 3.1 indicated that the
particle size of G-SLPN increased to 480–550 nm, while the E-SLPN maintained the particle size
around 300 nm regardless of curcumin loading concentrations. The smaller size of E-SLPN might
be attributed to the complete cross-linking efficiency, resulting in a more compact and denser DL
structure. In addition, both chemical cross-linking processes greatly reduced the numeric value of
zeta potential by about 10 mV, which was probably due to the consumption of carboxyl groups
resulting in the less negatively charged surface.
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The morphology of freshly prepared cross-linked DL-SLPN loaded with curcumin are
shown in Fig. 3.3. There was not much difference between G-SLPN and E-SLPN that both
particles exhibited spherical shape with homogeneous size and smooth surface, while the size
was smaller than the hydrodynamic dimension as measured by DLS. The polymeric coating layers
were not identified in TEM images, which may explain that DL coatings formed close and
longitudinal attachment surrounding the surface of SLN during the drying process required for
TEM visualization. Similar observation was also reported in a previous study on chitosan coated
SLN [91].

3.3.2. Characterizations of DL-SLPN
Fig. 3.4A presents the FTIR spectrum of curcumin loaded SLPN samples. All spectrum of
SLPN samples showed some similar characteristic peaks from solid lipid, NaCas, pectin, as well
as curcumin, such as C-H vibrations and C=O stretching from solid lipids and amide bands from
NaCas. After cross-linked with GA, the aldehyde group of GA covalently bound to the amino group
of NaCas to form an imine or Schiff bases (C=N bond). As the peak for imine bond could overlay
with the amide bond, it is hard to differentiate this peak. Moreover, as the FTIR equipment exhibits
low sensitivity (5%), there is the possibility that the newly formed functional groups (C=N) might
be lower than the detection limit. For G-SLPN and E-SLPN, the intensity of amide bands (1540
cm−1) increased. This result suggested that more NH2 groups of NaCas were changed into N-H
groups (N-H in secondary amides, 1540 cm−1) [111]. Also, the intensity and peak position of amine
groups at 669–900 cm−1 regions caused by bending vibration were changed after cross-linking,
indicating the generation of N-H groups. The intensity of carboxylate groups (1394 cm−1) in DLSLPN decreased in both G-SLPN and E-SLPN, implying that carboxylate groups participated in
the cross-linking reaction [111, 112]. This study was in good agreement with the literature of crosslinking studies using GA or EDC/NHS [111-114]. Based on FTIR spectra, it is reasonable to
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conclude that covalent linkages between amino group of NaCas and carboxyl groups of pectin or
within amino groups of NaCas were formed.
DSC analyses were performed on curcumin-loaded lipid nanoparticles to determine the
effects of coating and cross-linking on the calorimetric behavior, as well as physical state of lipid
core in SLPN. As shown in Fig. 3.4B, the melting temperature of sample (a) (SL-SLN) and (b)
(DL-SLPN) were lower than melting peak temperature of pure lipid (ATO 888, 73.1 °C, data not
shown). The decrease of melting temperature may be attributed to the small diameter of
nanoparticles, the high total surface area and the presence of emulsifiers/surfactants [115-117].
This phenomenon has been well explained by Kelvin effect, demonstrating that small and isolated
particles have lower melting temperature than bulk materials [118]. In addition, the calorimetric
curve of SL-SLN exhibited a peak at about 71.7 °C and a shoulder at 73.6 °C, indicating the
heterogeneous structure of lipid and protein. Pectin coating improved the physical properties of
solid lipid, as evidenced by the change of broad and irregular peak in sample (a) into a single and
more regular peak in sample (b). Cross-linking further enhanced the stability of lipid nanoparticles
and achieved more ordered structure. Both sample (c) (G-SLPN) and (d) (E-SLPN) showed
increased melting temperature to 73.3 °C, indicating the formation of more organized double-layer
structure. Sample (d) exhibited a significantly higher melting enthalpy than sample (c) (ΔH = 88.17
J/g), which means more energy is needed to melt sample (d), evidencing more pectin adsorption
onto NaCas layer due to higher cross-linking efficiency, and hence a more ordered and stable
particle [119, 120]. Several studies also found that more tightly packed and thermal stable
structure would give particles a higher melting temperature and transition enthalpy [121].

3.3.3. Encapsulation and delivery potential of DL-SLPN
SLN have been well known to encapsulate lipophilic drugs/nutrients in their lipid core with
a high loading capacity, compared to other colloidal delivery systems [8, 99]. Herein, we
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investigated the effects of cross-linking on the encapsulation efficiency and loading capacity. As
shown in Fig. 3.5A, the cross-linked DL-SLPN generally exhibited higher encapsulation efficiency
and greater loading capacity than non-crosslinked DL-SLPN, and particularly both values were
significantly higher in E-SLPN. Because there was a dialysis step after loading curcumin into SLN
during preparation, the cross-linked polymeric coating layers (shell of lipid nanoparticles) may
have a better protection against leakage or diffusion of curcumin from the lipid core during dialysis
process, thus providing a better kinetic stability to SLPN [122]. One recent study also suggested
that chitosan oligosaccharide coating on SLN significantly increased encapsulation efficiency and
drug loading compared to non-cross-linked SLN [123].
Fluorescence spectrum of curcumin is commonly used to investigate its binding capacity
to hydrophobic molecules, such as lipid [124, 125] and hydrophobic moiety of proteins [126, 127]
in aqueous system. The free curcumin that was dissolved in ethanol and diluted with water
showed a mild and broad peak at 549 nm, while the curcumin in all SLPN exhibited a strong and
sharp peak at 499 nm (Fig. 3.5B). The blue shift of its maximum peak of curcumin clearly indicated
a reduction in polarity in the microenvironment, from polar aqueous-ethanol phase to hydrophobic
core of SLPN [127]. Coincidently, heating at 80 °C has also been previously proven to further
enhance the binding of curcumin to hydrophobic regions [128], which may partly contribute to the
high encapsulation efficiency of curcumin in our study. The difference in fluorescence intensity of
curcumin in different SLN revealed that more curcumin was encapsulated in E-SLPN, followed by
G-SLPN and non-cross-linked DL-SLPN, which well agreed with encapsulation efficiency data in
Fig. 3.5A.
Prior to investigating the controlled release profile, the stability of DL-SLPN, G-SLPN and
E-SLPN were studied in the simulated GI fluids (with digestive enzymes) and the results are
tabulated in Table 3.1. Two pH conditions were studied, with pH 4 representing fed-state stomach
and pH 7 representing the small intestine condition, while the condition of pH 2 (fasting-state
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stomach) was not studied because all SLPN samples would aggregate and precipitate due to the
extreme acidic environment. The DL-SLPN precipitated immediately and severely when
incubated in the SGF, resulting in aggregates with large size (∼2 μm) that cannot be properly
detected by DLS. Interestingly, the particle size of G-SLPN at pH 4 became significantly smaller
than the original dimension, while the E-SLPN exhibited slightly smaller size at the same condition.
It is notable that particle size was further reduced by 110–150 nm and 90–120 nm, for G- and ESLPN, respectively, when they were transferred to intestinal condition of pH 7. G-SLPN showed
greater PDIs than E-SLPN, indicating that the particles were much more homogeneous when
cross-linked with EDC/NHS. Both cross-linked SLPN had similar zeta potential values, in the
range of −15 to −20 mV. The reduction in particle size and numeric value of zeta potential may
be in part due to the screening effects of salts present in the simulated GI fluids, causing the
compression of diffuse layer (pectin). However, the decrease of zeta potential of SLPN in our
study did not induce destabilization in both conditions, as no heavy aggregation was observed,
indicating that the pectin layer was able to provide steric stabilization to SLPN. Previous studies
suggested that, either high percentage (10%) of PEGylation [129] or high concentration of
synthetic surfactants (such as tween 80, Pluoronic F68, or Solutol®HS15) [130, 131] were needed
to prepare SLN that were stable in GI tract. Our work is the first study to demonstrate that natural
polymeric DL coating was effective to stabilize lipid nanoparticles in GI conditions.
The release kinetics of curcumin from SLPN were then tested in SGF (2 h) and SIF (4 h)
consecutively to mimic the in vivo digestive condition (Fig. 3.6A). The diffusion rate of free
curcumin across the dialysis membrane was fast, with about 60% detected in the gastric condition,
while the curcumin from all SLPN exhibited much slower and sustained release kinetics. The DLand G-SLPN showed similar kinetics, with a burst release of 20% curcumin within the first 30 min
and a total release of 40% curcumin in SGF, followed by a sustained release thereafter in SIF. In
contrast, only 20% curcumin was released from E-SLPN in SGF without any burst effect,
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suggesting that EDC/NHS cross-linking was the optimal strategy to form the acid-resistant coating
on lipid nanoparticles. The release of curcumin from SLN has been well studied in the PBS with
a pH of 7.4 to mimic the plasma condition [132, 133] which applications are mainly focused on
intravenous injection, while the simulated GI conditions are rarely investigated for SLN due to
their poor stability at low pHs. Yan and colleagues [134] prepared curcumin-loaded SLN and their
study showed that almost all curcumin was released in 0.1 N hydrochloric acid (HCl) within 5 min
without sustained release profile, which was ascribed to the fast dissolution of SLN by high
concentration of surfactant (Labrasol) and co-surfactant (Transcutol HP) used. Compared with
literature, our cross-linked DL-SLPN demonstrated superior release kinetics of curcumin in
simulated GI tract. In addition, mathematical models including zero-order, first-order, Higuchi,
Hixson-Crowell, Korsmeyer-Peppas, and Weibull equations were used to further understand the
release mechanism of curcumin from SLPN (Table 3.2). Model simulation and data analysis was
carried out using RStudio software. The release of DL-SLPN and G-SLPN in simulated GI tract
followed Higuchi and Weibull model better than other equations, as the two models showed the
best linearity. These two models explained that curcumin was first dissolved in solid lipid matrix,
then diffused to the surface of lipid core and then partitioned to NaCas and pectin layer, and finally
to the aqueous phase from the matrix [135, 136]. The released curcumin from SLPN then diffused
from dialysis bag to release medium due to concentration gradient. The diffusion of curcumin was
better controlled by encapsulation during release process. The in vitro curcumin release from ESLPN can be better explained by Higuchi and zero-order models than by others. Zero-order model
describes the release of drugs/nutrients at a constant rate, which is considered as the optimal
kinetics among all controlled-release models [136]. Therefore, the release of curcumin from ESLPN could be better diffusion controlled than DL- and G-SLPN. Mathematical model confirmed
the results from in vitro release experiment that E-SLPN was the optimal strategy for controlled
delivery.
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3.3.4. Antioxidant activity of curcumin in SLPN
The antioxidant activity of curcumin is well known and explored in many studies [64], [65].
In this work, antioxidant activity of three encapsulated curcumin (DL-SLPN, G-SLPN, and E-SLPN)
was investigated and compared with free curcumin in aqueous solution by applying ABTS assay
(Fig. 3.6B). All three SLPN samples showed significant higher ABTS radical scavenging activity
than free curcumin in aqueous solution. Although G-SLPN appeared to have the highest
antioxidant activity in three lipid nanoparticles formulation, no significant differences were found
among SLPN formulations. This might be attributed to that free curcumin cannot be well dissolved
thus separated out in aqueous media, resulting in a decreased contact probability between
curcumin and ABTS radicals and thus a lower antioxidant ability. In contrast, the hydrophobic lipid
core of SLPN with hydrophilic coating, not only provided nonpolar microenvironment for the
encapsulated curcumin but also facilitated its dispersion in aqueous condition, rendering a better
contact with free radicals and a higher antioxidant activity than free curcumin [137].

3.3.5. Nano spray drying
Nano spray drying technology was introduced in 2010 by Buchi® with their new Nano
Spray Dryer B-90. This technology has been evaluated for its potential to produce ultra-fine
powders of nanoparticles for drug delivery applications [138, 139]. However, thus far, the
applications of nano spray drying technology have been only focused on polymeric nanoparticles,
i.e. protein- and carbohydrate-based formulations [140, 141], but not on lipids-based particles.
The traditional spray dryers are usually used to produce microparticles of SLN with size ranging
from 5 to 10 μm, unless high concentration of sugar or surfactants are added [142, 143]. Our
recent work demonstrated the feasibility to obtain ultrafine powders of SLN and nanostructured
lipid carriers with appropriate polysaccharide coatings using Buchi® Nano Spray Dryer B-90 [144].
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Here, we further tested the feasibility of spray drying DL-coated SLPN using this innovative Nano
Spray Dryer B-90. As shown in Fig. 3.7, without pectin coating the size of spray-dried lipid
nanoparticles was heterogeneously distributed and large aggregates were observed (Fig. 3.7A),
while the DL-coating (Fig. 3.7B-D) dramatically improved morphology and reduced dimension of
spray-dried lipid nanoparticles. The size of spray-dried DL-SLPN was in the range of 500 nm − 1
μm. The cross-linking process further helped spray drying of DL-SLPN by forming more
homogenous powder particles, with the E-SLPN being the best (Fig. 3.7D).

3.4. Conclusion
In this study, curcumin-loaded SLPN with polymeric DL coatings (NaCas and pectin) were
successfully prepared by utilizing hydrophobic and electrostatic interactions, and the chemical
cross-linking using two different cross-linkers was further applied to reinforce the DL structure.
The obtained DL-SLPN with chemical cross-linking exhibited significantly higher encapsulation
efficiency than non-cross-linked ones. Both G- and E-SLPN were not only stable in simulated GI
conditions and but also showed sustained release kinetics of encapsulated curcumin Compared
with SL-SLN and DL-SLPN, the cross-linked DL coating dramatically improved morphology and
reduced dimension of spray-dried lipid nanoparticles powders. Encapsulation of curcumin in
SLPN also significantly improved its antioxidant activity in aqueous condition. Our study
demonstrated that the SLPN coated with cross-linked NaCas-pectin double layer hold promising
potential as an oral delivery system for lipophilic nutrients and drugs.

35

3.5. Figures and tables
Figure 3.1 Particle size, PDI, and zeta potential of lipid nanoparticles prepared under different
conditions: (A) SL-SLN; (B) DL-SLPN; (C) G-SLPN; (D) E-SLPN. In each figure, the statistical
differences among different curcumin concentration were indicated by the letters in upper
(particle size) and lower case (PDI).
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Figure 3.2 The schematic representation of GA (A) and EDC/NHS (B) cross-linking process.
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Figure 3.3 TEM images of 2.5% curcumin-loaded GA-SLPN (A) and E-SLPN (B). The scale bar
(white) represents 200 nm.
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Figure 3.4 (A) Figure of FTIR spectra of curcumin-loaded SLPN: (a) DL-SLPN, (b) G-SLPN, and
(c) E-SLPN; (B) DSC curves of SL-SLN, DL-SLPN, G-SLPN, and E-SLPN.
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Figure 3.5 (A) Encapsulation efficiency of SLPN for different concentrations of curcumin. Under
the same curcumin concentration, the statistical difference was noted with upper letters among
samples; (B) Fluorescence emission spectra of NaCas, free curcumin, curcumin-loaded DL-, G-,
and E-SLPN.
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Figure 3.6 (A) In vitro release profile of curcumin from different SLPN and free curcumin control;
(B) The ABTS radical scavenging activity of free and encapsulated curcumin. Statistical
difference among different samples were indicated by the upper letters.
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Figure 3.7 SEM images of spray dried lipid nanoparticles powder: (A) SL-SLN and DL-SLPN
(B), and G-SLPN (C) and E-SLPN (D). The scale bar represents 1 um.
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Table 3.1 Stability of different curcumin-loaded SLPN in simulated GI conditions.
Particle Size (nm)

Sets

G-SLPN

E-SLPN

PDI

Zeta Potential (mV)

pH 4

pH 7

pH 4

pH 7

pH 4

pH 7

5.00%

392.1±33.5

250.6±9.5

0.290±0.084

0.260±0.053

-15.3±0.8

-19.7±0.8

2.50%

361.1±2.4

251.2±7.5

0.256±0.015

0.268±0.019

-15.6±0.2

-20.1±0.5

1%

356.7±7.0

240.2±17.1

0.257±0.011

0.261±0.066

-15.1±0.2

-18.3±0.4

5.00%

284.6±17.5

164.9±8.4

0.179±0.092

0.167±0.027

-19.5±0.5

-19.1±0.3

2.50%

259.0±2.8

162.0±2.8

0.181±0.039

0.128±0.052

-16.9±0.2

-18.4±1.1

1%

247.2±5.4

151.7±6.8

0.177±0.027

0.117±0.039

-15.5±0.9

-19.6±1.7
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Table 3.2 Determination of coefficient (R2) of fitted model equations applied to the release of kinetics of curcumin-loaded SLPN.
Models
Set

Zero order model
Equation

DL-

y=

SLPN

0.0021x

G-

y=

SLPN

0.0019x

E-

y=

SLPN

0.0013x

R

2

first order model
Equation

R

2

y=
0.867

0.885

0.950

0.0028x -

Higuchi model
Equation

R

2

y=
0.576

0.0280x +

Hixson-Crowell
model
Equation

R

2

y=
0.903

0.0299x +

Weibull model
Equation

R

2

y=
0.651

0.5160x -

KorsmeyerPeppas model
Equation
y=

0.918

0.4167x -

1.3713

0.0848

0.3633

3.1169

2.9121

y=

y=

y=

y=

y=

0.0029x -

0.659

0.0253x +

0.935

0.0290x +

0.672

0.5024x -

0.944

0.4172x -

1.5332

0.0621

0.3414

3.2365

3.0550

y=

y=

y=

y=

y=

0.0057x 2.6017

0.638

0.0221x -

0.960

0.0333

0.0324x +
0.1899
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0.850

0.9003x 5.8535

R2

0.942

0.8280x 5.6384

0.887

0.925

0.929

Chapter 4 Study 2
Synthetic surfactant- and cross-linker-free
preparation of highly stable lipid-polymer hybrid
nanoparticles as potential oral delivery vehicles

This study has been published in Scientific Reports, 2017, 7, 2750. This chapter was adapted
and reprinted with permission from Nature Publishing Group.
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4.1. Background
In our previous study, we have discovered that chemical cross-linking of polymeric
multilayer coatings, by creating either imine or amide bonds, is necessary to achieve acceptable
stability under GI conditions [14]. Given the fact that chemical cross-linkers are usually associated
with potential toxicity, it would be more desirable and practical for clinical applications if a crosslinker-free process can be developed to prepare stable SLPN. Therefore, the current study
investigated the feasibility of using Maillard reaction, as a green chemical reaction, to create
amide bonds between the multilayer coatings formed by BSA and dextran to stabilize lipid
nanoparticles. In principle, the amino group of a protein reacts with carbonyl group of a reducing
carbohydrate, i.e. BSA and dextran in the present study, producing N-substituted glycosylamine
and then becomes a Schiff base. The obtained unstable product undergoes an Amadori
rearrangement, leading to a formation of ketosamine (1-amino-1-deoxy-ketose) [145-147], which
is also known as the Amadori product (Fig. 4.1). Although Maillard reaction conjugates have been
widely reported to improve the physical stability of conventional emulsions [148-150] and protein
nanoparticles [145, 151], their emulsification and stabilization effects on solid lipid nanoparticles
have not been explored yet. In particular, we explored the potential of Maillard reaction products
between dextran and BSA to emulsify solid lipid in this study. The potential of Maillard reaction
products together with pectin as multilayer coatings to stabilize SLPN under GI conditions was
investigated. The physicochemical properties of as-prepared SLPN were comprehensively
characterized and different drying technologies were also tested to produce spherical and
redispersible powder for future applications as oral delivery vehicles.

4.2. Experimental design
4.2.1. Preparation of BSA-dextran Maillard conjugates
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A Maillard reaction was conducted according to previously reported protocols [152, 153]
with slight modifications. Briefly, BSA and dextran (with different molecular weight) stock solutions
were respectively prepared by dissolving in ultrapure water at 40 mg/mL and 100 mg/mL. A
dextran stock solution was mixed with 1.25 mL of 40 mg/mL BSA solution dropwise under gentle
stirring to reach the final 2.5 mg/mL concentration of BSA and total volume of 20 mL in each group.
The molar ratio of protein to dextran in the mixture was in the range of 1:4 to 4:1. The pH of the
mixture was adjusted to 8.0 using 0.1 mol/L sodium hydroxide (NaOH), followed by the
lyophilization for 48 h in a Labconco FreeZone 6 Freeze Dry System (Kansas City, MO, USA).
The freeze-dried powder was incubated under 79% relative humidity in a desiccator containing
saturated potassium bromide solution for 24 h at 60 °C. The reaction products were denoted as
BSA-dextran conjugates and were used to prepare LPN. The detailed sample information in
different groups is tabulated in Table 4.1.

4.2.2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
The reducing SDS–PAGE was carried out to confirm the formation of conjugates between
BSA and dextran. A 5 µL BSA-dextran conjugate (containing 2.5 µg of BSA before Maillard
reaction in each group) or 0.5 mg/mL BSA solution dissolved in a 0.01 M phosphate buffer (pH
7.4) was mixed with 4.75 µL Laemmli sample buffer and 0.25 µL β-mercaptoethanol. The above
mixture was then heated at 100 °C for 5 min and loaded onto the gel. Electrophoresis was
performed at 200 V for about 1 hr with a 0.1% Tris–glycine electrophoresis buffer. The gel was
stained by Coomassie Brilliant Blue solution for 1 h and rinsed in 200 mL ultrapure water for about
30 min. The gels were then scanned and pictured using a scanner.

4.2.3. 2,4,6-Trinitrobenzene Sulfonic Acid (TNBS) assay
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TNBS spectrophotometric assay is a fast, sensitive, and convenient assay to determine
grafting degree of BSA by detecting the free amino groups in the Maillard conjugates. The TNBS
assay reagent was prepared according to Hermanson et al. [154]. First, the conjugates were
dissolved at a concentration of 200 µg/mL with reaction buffer (0.1 M sodium bicarbonate, pH 8.5).
BSA solutions with a series of dilutions ranging from 0 to 200 µg/mL in reaction buffer were
prepared for standard calibration curve. Then, 0.25 mL of 0.01% (w/v) TNBS solution was added
and mixed with 0.5 mL of each sample and standard solution, followed by 2 h incubation at 37 °C.
The TNBS solution was prepared and diluted freshly every time prior to use. After incubation,
0.25 mL 10% (w/v) SDS solution (diluted with distilled water) and 0.125 mL of 1 M HCl solution
were immediately added into each sample, and then the absorbance at 335 nm was measured.
The grafting degree of BSA was calculated using following equation:

Grafting degree (GD) =

Concentration of free amino groups in BSA detected in sample
×100%
Concentration of total amino groups in BSA added in sample

4.2.4. Preparation of SLPN using BSA-dextran conjugates and pectin coating
SLPN was prepared by emulsifying solid lipid with various BSA-dextran conjugates via
solvent-diffusion and sonication combined technique, as modified from our previous study [90].
Briefly, 10 mg of Compritol® 888 ATO was completely dissolved in the organic phase (0.5 mL
acetone and 0.5 mL ethanol), which was preheated to 80 °C in a water bath. The obtained organic
phase was added into 10 mL of aqueous phase containing BSA-dextran conjugates at 1 mg/mL,
followed by 3 min sonication by a probe-type sonicator (Misonix Sonicator® 3000, USA). Then,
the samples were rapidly cooled down in an ice bath to solidify the lipid nano-droplets. To prepare
pectin-coated SLPN, a pH- and heat-induced deposition process was adopted, as previously
described in our recent work [155]. Briefly, pectin was dissolved in ultrapure water at 2 mg/mL
and hydrated overnight, followed by pH adjustment to 6.8. The above pectin solution was then
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added into the aqueous phase (BSA-dextran conjugates solution), followed by 3 min sonication.
The pH of the mixture was adjusted to pH 4.7 and then heated at 80 °C for 30 min to reinforce the
polymeric coating network. After that, samples were rapidly cooled down in ice bath to solidify
lipid core and so the SLPN was obtained. The fabrication and coating procedures are illustrated
in Fig. 4.2. Nanoparticle controls were prepared similarly but using BSA and/or dextran instead
of BSA-dextran conjugates. The detailed information of control groups was summarized in Table
4.2.

4.2.5. Characterization of SLPN
The particle size, PDI, and zeta potential of LPN were measured by a Zetasizer Nano ZS
at 25 °C (Malvern Instruments Ltd, Worcestershire, UK). The hydrodynamic dimeter (particle size)
and PDI were determined by DLS at a scattering angel of 173°. All samples were diluted 10 times
with ultrapure water to fit the optimal instrument sensitivity and avoid multiple scattering. To record
the comparable count rate data, all samples were measured with a fixed attenuator. Zeta potential
was calculated from electrophoretic mobility measured by a laser Doppler velocimeter using the
same instrument.
Colloidal SLPN samples were cast-dried on an aluminum pan and stored in a vacuum
desiccator prior to FTIR spectrum analysis by a Nicolet iS5 FTIR spectrometer (Thermo Scientific,
Waltham, MA, USA). The infrared spectra were collected from the wavenumber of 500–4000 cm−1
at a resolution of 4 cm−1 and analyzed using OMNIC software version 8.0.
To determine the GI stability of as-prepared SLPN, 1 mL of sample was added to 9 mL of
simulated gastric fluid (pH 2 or 4, with 1 mg/mL pepsin) and incubated at 37 °C for 2 h. After that,
1 mL of the above mixture was mixed with 9 mL of simulated intestinal fluid (pH 7 with 10 mg/mL
pancreatin) and incubated at 37 °C for 4 h. To minimize the scattering effect of undissolved
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prancreatin, it was hydrated overnight, centrifuged, and filtered through 0.45 µm membrane to
remove any insoluble impurities prior to use. After each incubation, the particulate characteristics,
including particle size, PDI and zeta potential, were determined as described above.

4.2.6. Fluorescence spectroscopy
The fluorescence spectra of native BSA, BSA-dextran conjugates (Dex20–3, Dex40-3,
Dex75-3, Dex150-3, and Dex500-3), SLPN (prepared with conjugate Dex75-3), and pectin-coated
SLPN (prepared with conjugate Dex75-3) were recorded using a LS55 Fluorescence
Spectrofluorometer (PerkinElmer, Waltham, MA, USA). The excitation wavelength was 280 nm,
and the emission spectra were collected by scanning from 300 to 500 nm. The step width was set
at 0.5 nm for both excitation and emission. All samples were diluted with ultrapure water in order
to meet the instrument sensitivity range. For native BSA and BSA-dextran conjugates, they were
dissolved at 1 mg/mL in ultrapure water as the stock solution and then diluted to the same final
concentration as in the SLPN samples.

4.2.7. Dying and redispersion
Selected pectin-coated SLPN samples were dried by either a Nano Spray Dryer B-90
(Büchi Labortechnik AG, Flawil, Switzerland) or a Labconco FreeZone 6 Freeze Dry System
(Kansas City, MO, USA). For nano spray drying, the following operating conditions were
performed: inlet temperature at 100 °C, flow rate at 120 L/min, and mesh size of 5.5 µm. For
freeze-drying, samples were first frozen at −80 °C overnight and then freeze-dried at −80 °C/0.014
mBar for 24 h. The obtained sample powders were checked for their redispersibility by dissolving
powders in water at a concentration of 1 mg/mL and heating at 80 °C for 5 min was applied to
achieve better redispersibility. The particle size, PDI, and zeta potential were determined by DLS
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technique and the morphology of powders as well as the redispersed SLPN samples were
observed under SEM as described in the following section.

4.2.8. Morphological observation
TEM was used to observe the morphology of freshly prepared pectin-coated SLPN
(Dex75-3). Samples were stained by mixing with equal volume of 2% phosphotungstate (pH
adjusted to 7), and then one drop of stained sample was deposited on a 400-mesh copper grid
for 10 min, prior to morphological observation using a TEM (Tecnai T12, FEI, Hillsboro, Oregon,
USA) at 80 kV. SEM was conducted to visualize the morphology and shape of spray-dried, freezedried SLPN powders and redispersed particles. For powders, sample was directly placed on
double-sided carbon tape pre-affixed on a specimen stub, and for redispersed samples, a few
drops of sample were cast-dried on an aluminum pan overnight and then placed on the doublesided carbon tape pre-affixed on a specimen stub. Both powder and redispersed samples were
sputter-coated with a thin layer of gold before observed under SEM (JSM-6335F, JEOL Ltd.,
Tokyo, Japan).

4.3. Results and discussion
4.3.1. Formation of BSA-dextran conjugates by Maillard reaction
The molecular weight profile of native BSA and five conjugates (Dex20-3, Dex40-3,
Dex75-3, Dex150-3, and Dex500-3) are analyzed by SDS-PAGE and shown in Fig. 4.3A. The
native BSA molecule showed a strong and clear band at 66 kDa, corresponding to the molecular
weight of native BSA. In addition, the native BSA also exhibited several smear bands at higher
molecular weights ranging from 150 to 300 kDa, which could be due to the impurities or
aggregates of BSA monomers during heating process of sample preparation for SDA-PAGE [15651

158]. The Maillard reaction between BSA and dextran had a prominent effect on the molecular
weight profile. Gradual and significant reduction in the intensity of native BSA characteristic bands
was observed with the increase of dextran molecular weight (Fig. 4.3A). Notably, there was only
one visible band at 66 kDa in the sample Dex500-3, and a significant amount of sample was
observed on the top of the separating gel, suggesting the formation of high molecular weight BSAdextran conjugate. Fig. 4.3B showed the grafting degree of five Maillard conjugates measured by
TNBS assay. In TNBS assay, free primary amines on BSA reacted with TNBS forming a highly
chromogenic derivative. As the increase of dextran molecular weight, the grafting degree of
conjugates increased from about 30% to 77%, confirming that the higher molecular weight dextran,
which has longer molecular chain containing more carbonyl groups, was more effective to
consume amino groups on BSA. This result well agreed with SDS-PAGE data in Fig. 4.3A. The
capability of BSA-dextran Maillard conjugates to form micelle structure was studied as a function
of pH values (Fig. 4.3C and D). The particle size, count rate, and zeta potential were measured
by DLS to monitor the formation of micelles. At acidic (pH 2–3) or basic (pH 7–9) conditions that
are away from BSA’s pI (pH 4.7) [159], the BSA moiety carries strong positive or negative charges,
respectively, and so the conjugate exists as monomeric protein molecules with strong repulsive
forces among monomers. Concomitantly, the count rate at such conditions was very small,
representing the concentration of colloidal particles was low. In contrast, at range of pH 4–5, which
is close to the pI of BSA, there was a significant raise in the count rate and particle size reached
100 nm at pH 4.7 with the highest count rate and zero zeta potential. This was indicative of that
BSA moieties in the conjugates aggregated together to form micelles while the attached dextran
tail stabilized the micelles from precipitation. Our observation on the formation of BSA-dextran
micelles at acidic condition was well corroborated by other literature reports [160, 161].

4.3.2. Characterization of SLPN prepared with different BSA-dextran conjugates
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The particulate characteristics, including particle size, PDI and zeta potential of SLPN
prepared with different BSA-dextran conjugates are depicted in Fig. 4.4. It was noticed that the
mass ratio between BSA and dextran in the conjugates did not show significant effects on the
particle size and PDI. Generally, the particle size and PDI of SLPN were in the range of 150–
200 nm and 0.2–0.25, respectively, except samples Dex150-1 (Fig. 4.4D) and Dex500-1 (Fig.
4.4E), which exhibited greater particle size (>200 nm) with larger PDI values (>0.3). This may be
partly due to the larger molecular weight and greater molar ratio of dextran in the conjugates,
resulting in the very thick and heterogeneous polymeric coating and polydispersed particles. In
contrast, the zeta potential of SLPN, directly related to the net charges on the surface of
nanoparticles, was affected by the types of conjugates to a greater extent. When the smallest
molecular weight of dextran was used to form the conjugates, the prepared SLPN (Fig. 4.4a)
carried stronger negative surface charge, explaining the substantial exposure of carboxyl groups
of BSA on the nanoparticles surface due to the limited shielding effect from conjugated dextran.
As the increase of dextran molar ratio in the conjugates, the shielding effect from dextran became
more prominent and the zeta potential of SLPN gradually reduced (Fig. 4.4a–e). Concomitantly,
among the SLPN prepared by the conjugates with the same molecular weight dextran, the
magnitude of zeta potential was generally increased with the decrease of dextran molar ratio. It
is worth noting that the particle size and PDI of SLPN prepared by this synthetic surfactant-free
method were similar to or even smaller than many reported SLN systems prepared with
concentrated synthetic emulsifiers/surfactants [89, 162, 163].

4.3.3. Adsorption of pectin onto SLPN by electrostatic deposition
Although the BSA-dextran conjugates were stable at a wide range of pH and formed
micelles upon heating at pH 4.7 (Fig. 4.3), our preliminary data showed that the prepared SLPN
severely aggregated and precipitated at gastric condition (pH 2–4). This revealed that conjugates
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alone could not protect carboxyl groups of lipid molecules from protonation at acidic pHs.
Therefore, to improve their physical stability at acidic pHs, we introduced pectin as the third
polymeric coating layer on the SLPN and tested whether heating the pectin-coated SLPN at pH
4.7 would reinforce the coating structure. It was apparent that the particle size of SLPN increased
by 50–100 nm after pectin coating, while heating process did not have a significant impact even
though a slight reduction on particle size was noticed (Fig. 4.5). Similar trends were observed for
PDI that the heated SLPN had a smaller PDI, indicating the formation of a more compact and
homogeneous network upon heating. The magnitude of zeta potential of SLPN after pectin
coating generally increased by 15–20 mV, except the samples in group Dex20 (Fig. 4.5a) where
a slight reduction was observed. Moreover, heating process further increased the magnitude of
zeta potential by approximately 5–10 mV. Count rate, a reflection of particle density in a colloidal
system, increased significantly by the heating process (Fig. 4.5a–e), revealing that pectin
adsorption had occurred and the strong interaction between pectin and BSA-dextran layers
resulted in the formation of more compact SLPN.
Heating the protein/polysaccharide mixture at a pH close to the protein’s pI is a well-known
process to induce partial denaturation and self-aggregation of protein molecules and
simultaneous deposition of polysaccharide molecules, and thus the protein/polysaccharide
complex nanoparticles were formed [164, 165]. Our previous study showed that casein/pectin
nanocomplex particles prepared by this process can be not only applied as an oral delivery vehicle
[79], but also holds great potential to coat SLPN [155]. The SLPN in our present study exhibited
much smaller particle size than casein/pectin-coated SLN (>350 nm) in our previous study [155],
which may be explained by the following two major reasons. First, the protein/polysaccharide
Maillard products often possess significantly improved emulsifying properties than their physical
mixture [146], and so the solid lipids are better emulsified during preparation. Second, the highenergy sonication is used in the present study to reduce the particle size, compared to the high-

54

speed homogenization technique in our previous work. In addition, the increased magnitude of
zeta potential and count rate with the same particle size after heating is indicative of the internal
structural change and the re-arrangement of pectin network on the outmost surface of SLPN,
confirming the formation of denser and more compact polymeric coating [79, 106]. In general,
BSA-dextran conjugates with medium molecular weight (75 and 150 kDa) exhibited smaller
particle size and PDI, as well as stronger interactions with pectin as indicated by the greater extent
of increase in zeta potential upon heating. Thus, they are considered as the optimal formulations
for production of SLPN. Additionally, in order to justify the coating effect of pectin and BSA/dextran
conjugate, various control groups (Table 4.2) were conducted and the results were tabulated in
Table 4.3. Although all control groups showed a relatively small particle size and PDI at pH 7,
they all precipitated after pH was adjusted to 4.7 and thermal treatment. These results indicated
that BSA or dextran alone, or their physical mixture, could not protect lipid nanoparticles under
acidic environment.

4.3.4. Stability of LPN in simulated GI conditions
The GI stability of SLPN was tested under three simulated digestive environments, i.e.
fasting (pH 2) and fed (pH 4) gastric conditions with pepsin, and intestinal condition (pH 7) with
pancreatin (Fig. 4.6). The SLPN prepared by the conjugates with either small (20 kDa) or large
(500 kDa) molecular weight dextran exhibited poor GI stability under all three conditions, showing
severe aggregation indicated by large particle size and/or irregular PDI; while those prepared by
the conjugates with medium molecular weight dextran (75, 150 kDa) demonstrated excellent
stability. The particle size of SLPN in the groups Dex75 and Dex150 remained the same or
increased slightly at acidic pH, while it significantly reduced by 50 nm at pH 7. This was because
the attractive force between the pectin and positively charged protein moieties in the conjugates
was well maintained at acidic pHs. But when the pH increased to neutral, their electrostatic
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attraction was weakened, resulting in the dissociation of pectin coating to some extent and thus
reduction in particle size. The change of zeta potential shared the same trend in all SLPN samples
in the way that its magnitude was gradually reduced as pH decreased and eventually reached
zero at pH 2. The stability results reaffirmed that the SLPN prepared by BSA-dextran with
molecular weight of 75 and 150 kDa were the optimal formulations among all groups.
Although it has been widely reported that the functional properties of Maillard reaction
conjugates are dramatically affected by both molecular weight and molar ratio of polysaccharide
[166, 167], our results indicated that the molecular weight of dextran played a predominant role
in determining the stability of studied SLPN. The carbohydrate tail in the conjugates prepared with
small molecular weight of dextran may not be long enough to provide sufficient steric hindrance
repulsion to stabilize SLPN at acidic pH, leading to the growth of particle size and thus formation
of precipitates. Conversely, however, if the molecular weight of dextran is too large (500 kDa), the
resultant conjugates may become too hydrophilic, resulting in the reduced emulsifying property,
which was also confirmed by the large original particle size of those SLPN without pectin coating.
It is worth mentioning that either the conjugate or pectin alone was unable to stabilize SLPN under
pH 2 (data not shown). This suggested that the exceptional stability of pectin-coated SLPN at pH
2 with zeta potential being zero was due to the strong steric stabilization effects provided by both
BSA-dextran and pectin coating layers. A previous study reported that the BSA-dextran micelles
must be cross-linked by glutaraldehyde, a toxic chemical cross-linker, otherwise they would
dissociate even at pH 5, a mild acidic condition [161]. Although our previous work demonstrated
that chemically cross-linked casein/pectin-coated SLPN were able to withstand mild acidic
condition (pH 4), they formed larger aggregates and precipitated at pH 2 [14]. In summary, the
BSA/dextran/pectin-coated SLPN prepared in the present study hold promising potential as oral
delivery vehicles due to the simple and safe preparation as well as exceptional stability under GI
conditions, and thus they are expected to have a better retention of encapsulated bioactives when
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passing through the GI tract, which warrants future investigation to explore their encapsulation
and delivery potentials.

4.3.5. Fluorescence and FTIR spectra of SLPN
BSA is a globular protein with two tryptophan and twenty tyrosine residues, together
contributing to its strong intrinsic fluorescence [168]. The Maillard reaction of BSA with dextran
significantly lowered the intrinsic fluorescence of BSA (Fig. 4.7), which corresponded to the
protein aggregation formed during dry-heating process [158, 169]. Notably, dextran with a greater
molecular weight exhibited a more significant effect in quenching the intrinsic fluorescence of BSA.
Nevertheless, the λmax of BSA when excited at 280 nm did not shift after glycosylation with dextran.
This indicated that there was no significant change in the conformation of the protein, which was
well corroborated by previous studies on the Maillard reaction between dextran and BSA or other
proteins [152, 170]. In contrast, after preparation of SLPN and adsorption of pectin, the λmax was
significantly shifted from 348 nm to 338 nm, revealing the conformational change in the molecular
structure of BSA molecules. However, the degree of conformational change was independent
from the molecular weight of dextran (data not shown). It has been reported that heating BSA at
or above its denaturation temperature (70 °C) and high-intensity sonication can induce irreversible
changes in protein structure and conformation [171, 172]. Since these two processes were
involved in the preparation of SLPN, it was predictable to observe conformational changes in BSA
structure to some extent. The conformational change induced by the heating and sonication
process was likely to increase the surface hydrophobicity of BSA-dextran conjugates, which could
enhance their capability to stabilize SLPN due to the strong hydrophobic interactions.
The FTIR spectra of all ingredients and LPN are presented in Fig. 4.8. Two major
characteristic peaks at 1642 and 1516 cm−1 were observed in native BSA (Fig. 4.8A) and were
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assigned to amide I and amide II stretching vibrations, respectively [173]. The dextran spectrum
(Fig. 4.8B) exhibited typical polysaccharide characteristic absorption bands, including 3314 cm−1
due to the O‒H stretching, 2920, 1419 and 1344 cm−1 assigned to v (C‒H) and δ (C‒H) vibrational
modes, as well as a characteristic region at 700–1010 cm−1 corresponding to α-glucopyranose
ring deformation modes [174]. The physical mixture of BSA and dextran (Fig. 4.8C) generally
exhibited all the characteristic peaks in both compounds. On the contrary, the BSA-dextran
Maillard conjugate (Fig. 4.8D) demonstrated very sharp peaks at the amide stretching region of
1500–1650 cm−1, confirming the successful formation of new amide bonds between the two
molecules [175]. Dramatic changes were observed in the spectrum of BSA/dextran coated SLPN
(Fig. 4.8E), which were attributed to the presence of lipid, a highly hydrophobic compound. In
particular, the new peak at 1739 cm−1 was assigned to the C=O stretching from carboxyl groups
in the saturated aliphatic chain, and the significant reduction of O‒H stretching intensity at
3294 cm−1 was owing to the strong hydrophobicity of lipids [90, 176]. It is notable that pectin
coating greatly enhanced the hydrophilicity of SLPN (Fig. 4.8F), as suggested by the significant
augment in the intensity of O‒H stretching at 3294 cm−1 and carboxylate ion vibration at 1014 cm−1.
These observations were in line with our recent studies on the casein/pectin-coated SLPN [14,
155].

4.3.6. Morphological observation
TEM was used to image the morphology of pectin-coated SLPN prepared with BSAdextran conjugate Dex75–3. As shown in Fig. 4.9, the pectin-coated SLPN were spherical in
shape with monodispersed size distribution, and notably the well-defined core-shell structure was
clearly observed, as indicated by strong contrast between the darker core and lighter surface of
SLPN. The particle size observed from TEM image is in agreement with that determined by DLS
(Fig. 4.5C). Furthermore, the morphology of pectin-coated SLPN incubated at different digestive
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conditions was observed by SEM to verify if there was any morphological change of SLPN under
each condition. In line with the stability measurement by DLS (Fig. 4.6), the SEM observation
showed that the pectin-coated SLPN were able to maintain their spherical shape and
homogeneous distribution at all conditions (Fig. 4.10), including pH 2, 4 and 7 with respective
digestive enzymes, implying the successful development of highly stable SLPN by a synthetic
surfactant-free and cross-linker free synthesis method. It is worth mentioning that the pectincoated SLPN prepared in the present study were even more stable than the covalently crosslinked polymer-coated SLN using chemical cross-linker, such as glutaraldehyde and EDC/NHS
reported in other studies [14, 123].

4.3.7. Drying and redispersion of pectin-coated SLPN
As shown in Fig. 4.11A, the Nano Spray Technology transformed pectin-coated colloidal
SLPN to spherical dry powder particles, with smooth surface and homogeneous size ranging from
1–1.5 µm. Although the particle size was significantly increased in the obtained powders, these
powder particles, when redispersed in water, were able to re-assemble their colloidal
nanostructures (Fig. 4.11C), comparing to their original size of 252 nm, suggesting that some
irreversible aggregation occurred during drying process. Interestingly, the freeze-dried SLPN (Fig.
4.11B) did not show a significant change in particle size in dry powders and redispersed colloidal
SLPN (Fig. 4.11D), both of which were around 500 nm. While the redispersed freeze-dried
colloidal SLPN were larger than the original SLPN, they were much more homogeneously
distributed with a dramatically smaller PDI and a narrower distribution curve (Fig. 4.11E and F).
Spray drying and freeze-drying are the two most commonly used drying techniques to
transform colloidal nanoparticles to dry powders. Spray drying technique, characterized by fast
water removal rate via heating atomized small droplets at high temperature, is well-known as a
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simple, dust-free, cost-friendly one-step drying process in food and pharmaceutical industries
[177, 178]. Nano Spray Drying technology is a recently invented innovative technology that utilizes
a vibrating mesh technology to generate millions of tiny droplets which are efficiently dried in a
chamber with laminar hot air flow. In this way, drying time is significantly shortened and minimizes
agglomeration of lipid particles. We previously demonstrated the feasibility of this technology to
transform caseinate/lecithin and polysaccharides coated colloidal SLN and NLC and our results
suggested that the biopolymer coatings played a critical role in producing spherical and uniform
dry powder particles that were redispersible in water [14, 144, 155]. Conversely, freeze-drying
technique is a relatively expensive and slow process, and final products are particularly affected
by the ice nucleation and crystallization step, i.e. rapid and deep frozen of samples at −80 °C or
lower temperature (such as liquid nitrogen) prior to freeze-drying [179]. Despite vast research in
obtaining redispersible lipid-based nanoparticles by different drying technologies, many attempts
are made with either incorporation of high concentration of sugars (up to 25%) into nanoparticle
formulation [180] or redispersion of dry powders in a solution with concentrated synthetic
surfactants [142]. Notably, our results clearly demonstrated that the SLPN prepared by using
BSA-dextran Maillard reaction conjugate as natural emulsifier together with pectin coating can be
dried by nano spray drying and freeze-drying, and the obtained dry powders can redisperse in
water with uniform nanoscale size. Nevertheless, it is worth noting that heating at 80 °C for 5 min
was needed to fully redisperse the powders without visual presence of precipitates. Therefore, it
is postulated that although the SLPN may agglomerate into bigger particles during drying, solid
lipids were melted upon heating and the polymeric coatings (pectin and BSA-dextran) were rearranged to the surface of melted lipids which re-assembled to nanoparticles during subsequent
cooling process.

4.4. Conclusion
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In this work, a synthetic surfactant-free and cross-linker-free technique was developed to
prepare highly stable SLPN. The formulation consisted of all-natural biomaterials, including solid
lipid, BSA-dextran Maillard conjugate, and pectin. The micelle-forming property of BSA-dextran
conjugate was exploited to envelop melted solid lipid into the core, followed by an electrostatic
deposition of pectin as the outmost polymer coating to reinforce the polymer-lipid network. The
molecular weight of dextran and the molar ratio between BSA and dextran were found to be critical
in forming compact, uniform, and small SLPN with diameter under 200 nm. The as-prepared
SLPN exhibited exceptional stability under simulated GI conditions with digestive enzymes, as
verified by the DLS measurement and SEM observation, signifying their great potential as oral
delivery vehicles for lipophilic bioactive compounds.
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4.5. Figures and tables
Figure 4.1 Schematic representation of Maillard conjugation reaction between glucose
unit in dextran and BSA.
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Figure 4.2 Schematic diagram of fabrication of pectin-coated SLPN.
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Figure 4.3 (A) SDS–PAGE analysis of BSA-Dextran conjugates produced by Maillard reaction
with different experimental groups; (B) Grafting degree of Maillard conjugates; the pH
dependence of particle size (C), and count rate and zeta potential (D) of Maillard conjugate
(Dex75-3). In Fig. 4.3B, data not sharing the same letter were significantly different (p < 0.05).
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Figure 4.4 Particle size, PDI (A–E), and zeta potential (a–e) of SLPN (prior to pectin coating)
prepared using Maillard conjugates with different molecular weight dextran. The groups Dex755 and Dex150-5 formed gels and were not completely solubilized in water, and thus their results
were excluded.
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Figure 4.5 Particle size, PDI (A–E), zeta potential, and count rate (a–e) of pectin-coated SLPN
(before and after thermal treatment) prepared using Maillard conjugates with different molecular
weight dextran. The groups Dex75-5 and Dex150-5 formed gels and were not completely
solubilized in water, and thus their results were excluded. NH: non-heat, H: heat, PS: particle
size, ZP: zeta potential, CR: count rate.
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Figure 4.6 Particle size (A1-E1), PDI (A2-E2), and zeta potential (A3-E3) of SLPN in simulated GI conditions (pH2, pH4, and pH7).
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Figure 4.7 Fluorescence emission spectra of native BSA, selected BSA-Dextran conjugates,
SLPN and pectin-coated SLPN.
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Figure 4.8 FTIR spectra of: (A) BSA, (B) Dextran (M.W = 75 kDa), (C) Physical mixture of
dextran and BSA, (D) Maillard conjugate (Group Dex75-3), (E) LPN, (F) Pectin-coated SLPN.
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Figure 4.9 TEM images of pectin-coated SLPN (prepared with conjugate Dex75-3).
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Figure 4.10 SEM images of liquid samples under pH 2 (A), 4 (B) and 7 (C) of pectin-coated
SLPN (prepared with conjugate Dex75-3).
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Table 4.1 Formulations for preparation of Maillard conjugates (a MR: Molar ratio).
Group

Dex20

Dex40

Dex75

Dex150

Dex500

M.W. of dextran (kDa)

20

40

75

150

500

Subgroup

Dex20-1
Dex20-2
Dex20-3
Dex20-4
Dex20-5

Dex40-1
Dex40-2
Dex40-3
Dex40-4
Dex40-5

Dex75-1
Dex75-2
Dex75-3
Dex75-4
Dex75-5

Dex150-1
Dex150-2
Dex150-3
Dex150-4
Dex150-5

Dex500-1
Dex500-2
Dex500-3
Dex500-4
Dex500-5
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MRa of
BSA to
dextran
1:4
1:2
1:1
2:1
4:1

Table 4.2 Formulations for control groups.
Control group
C1
C2
C3
C4
C5
C6

BSA
BSA w/pectin
Dextran, 75k
Dextran, 75k w/pectin
BSA, dextran mixture
BSA, dextran mixture
w/pectin

Lipid
(mg)
10
10
10
10
10

BSA
(mg)
10
10
—
—
4.7

Dextran
(mg)
—
—
10
10
5.3

Pectin
(mg)
—
5
—
5
—

10

4.7

5.3

5
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V (mL)
10
10
10
10
10
10

Table 4.3 Particle size, PDI, and zeta potential of control groups under different pH and
condition.
pH 7
Group
C1
C2
C3
C4
C5
C6

Particle size
(nm)
145.1 ± 0.3
157.4 ± 1.5
140.5 ± 2.2
174.5 ± 1.2
169.2 ± 1.5
217.1 ± 1.6

pH 4.7
PDI

Zeta potential (mV)

0.284 ± 0.018
0.292 ± 0.018
0.272 ± 0.014
0.270 ± 0.006
0.286 ± 0.010
0.259 ± 0.015

−18.6 ± 0.7
−35.9 ± 1.5
−28.6 ± 0.5
−34.6 ± 1.1
−25.1 ± 0.8
−36.0 ± 0.3
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Precipitates
Precipitates
Precipitates
Precipitates
Precipitates
Precipitates

pH 4.7
w/thermal
treatment
Precipitates
Precipitates
Precipitates
Precipitates
Precipitates
Precipitates

Chapter 5 Study 3
Solid lipid-polymer hybrid nanoparticles
prepared with natural biomaterials: A new
platform for oral delivery of lipophilic bioactives

This study has been published in Food hydrocolloids, 2018, 84, 581-592. This chapter was
adapted and reprinted with permission from Elsevier.
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5.1. Background
In our previous study, SLPN were prepared from all-natural biomaterials, i.e. glyceride
lipids, BSA, dextran, and pectin, without use of toxic chemicals or solvents. BSA and dextran first
react with each other through Maillard reaction, a non-toxic chemical process, to form BSAdextran (BD) conjugate that acts as an amphiphilic copolymer to stay at the interface of lipid and
aqueous phases providing dual functions of emulsification and steric stabilization; while pectin
forms secondary polymeric coating on top of BSA-dextran conjugate layer to impart exceptional
colloidal stability and enhance structural integrity under GI conditions. However, the encapsulation
and delivery capability of fabricated SLPN were not evaluated in study 2. In the core-shell
structure of SLPN, the outer polymeric shell is crucial to stabilize the nanoparticles under GI
conditions, while the inner solid lipid core plays a vital role in determining the encapsulating
capability for lipophilic bioactive compounds. Moreover, the inner solid lipid core may have
significant effects on morphology and redispersibility in water of nanoparticles after nano spray
drying. Therefore, in current study, six different solid lipids, including two glyceride lipids
(Compritol® 888 ATO and Precirol® ATO 5) and four saturated fatty acids (behenic acid, stearic
acid, palmitic acid and myristic acid), were systematically tested for their applicability to prepare
SLPN. The physicochemical properties, including nanoparticle structure, inter- and intramolecular interactions, colloidal stability, drying and redispersibility were comprehensively
evaluated. To further evaluate the encapsulation and delivery potential of prepared SLPN for oral
delivery, curcumin was then studied as a model lipophilic bioactive to explore the encapsulation
and delivery potentials of selected SLPN to GI tract.

5.2. Experimental design
5.2.1. Preparation of SLPN with BD conjugates and pectin

76

Six types of solid lipids are used in this study and their molecular structures are shown in
Fig. 5.1. SLPN without pectin were prepared by emulsifying various solid lipid without organic
solvents using homogenization and sonication technique. Briefly, 10 mg of Compritol® 888 ATO
(ATO888), Precirol® ATO 5(ATO5), behenic acid (BA), stearic acid (SA), palmitic acid (PA), or
myristic acid (MA) powder was added directly into 10 mL of aqueous phase containing 1 mg/mL
BD solution (Dex75-3 from study 2) at the temperature 5 °C above the melting point of each solid
lipid under homogenization at 25,000 rpm for 30 s to obtain coarse emulsion, followed by 3 min
sonication (80% amplitude) by a probe-type sonicator (Q125; 3 mm tip diameter, QSonica, USA).
Then, samples were rapidly cooled down in an ice bath to facilitate the recrystallization of solid
lipid.
To prepare SLPN with pectin coating, pectin was first dissolved in water at 5 mg/mL, and
the pH of pectin solution was adjusted to 7.0 before use. The above pectin solution was then
mixed with BD solution to form new aqueous phase. The subsequent procedures were the same
as described above for the preparation of SLPN without pectin using the new aqueous phase.
After sonication and recrystallization, the pH of SLPN samples was adjusted to 4.7 and then
heated at 80 °C for 30 min. After that, samples were again cooled down in ice bath to solidify lipid
core. The preparation and coating procedures are illustrated in Fig. 5.2. To encapsulate curcumin
into SLPN, the pH of BD solution was first adjusted to pH 12 using 3 M NaOH, followed by addition
of various amounts of curcumin powder and stirring for 30 min. The pH of above mixture was then
neutralized to pH 7 using 3 M HCl. The obtained mixture, i.e. curcumin-containing BD mixture,
was used as aqueous phase for the fabrication of curcumin-loaded SLPN with or without pectin.
This pH-driven method was validated by previous literature which demonstrated that with the
presence of macromolecular emulsifier (such as protein and polysaccharide), the structure of
curcumin was not changed before and after alkaline treatment [44, 181].
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5.2.2. Characterization of particulate properties
Particle size, PDI, and zeta potential of various SLPN were measured by Zetasizer Nano
ZS at 25 °C (Malvern Instruments Ltd, Worcestershire, UK). Particle size and PDI were
determined by DLS at 173° scattering angle. All samples were diluted 10 times with water before
measurement to avoid multiple scattering. Zeta potential was calculated from electrophoretic
mobility using the same instrument. The absorbance of prepared SLPN samples was measured
at 500 nm to compare their turbidity and their digital photos were taken to visualize the difference
among samples.
GI stability of SLPN samples was evaluated according a published protocol [14]. Briefly,
1 mL of sample was added to 9 mL of SGF (pH 2 or 4, with 1 mg/mL pepsin) and incubated at
37 °C for 2 h. Then, 1 mL of above mixture was withdrawn and mixed with 9 mL of SIF (pH 7, with
10 mg/mL pancreatin) and incubated at 37 °C for another 4 h. The pancreatin was dissolved and
hydrated in SIF overnight to ensure the complete hydration and then pancreatin-containing SIF
was centrifuged and filtered through 0.45 μm membrane to remove any impurities. At the end of
each incubation stage, particle size and PDI was measured by DLS method mentioned above.

5.2.3. Determination of encapsulation efficiency
EE was determined by measuring the concentration of unencapsulated free curcumin
using Amicon® Ultra centrifugation device (Merck KGaA, Darmstadt, Germany) with a molecular
weight cutoff of 10 kDa. The concentration of curcumin in the receiving reservoir was measured
by a UV/Vis spectrophotometer (Evolution 201, Thermo Scientific, Waltham, MA, USA) after
centrifuging at 8000 × g for 20 min. The EE was calculated using following equation:

Encapsulation efficiency (EE)=

Mass of curcumin in final product
×100%
Total mass of curcumin
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5.2.4. Fluorescence spectroscopy
The fluorescence spectra of free curcumin and SLPN prepared with ATO888, ATO5, BA,
SA, PA, or MA were recorded using LS55 Fluorescence Spectrofluorometer (PerkinElmer,
Waltham, MA, USA). The excitation wavelength was 420 nm, and the emission spectra were
collected by scanning from 450 to 650 nm. The step width of both excitation and emission was
set at 0.5 nm. The free curcumin sample was prepared by dissolving curcumin powder in ethanol
at 1 mg/mL and the obtained curcumin solution was diluted with water to the same final
concentration as in the SLPN samples. All samples were diluted to meet the instrument sensitivity
range.

5.2.5. Surface hydrophobicity measurements
The surface hydrophobicity of SLPN before and after pH adjustment and thermal
treatment was measured using 1-anilino-8-naphthalene-sulfonate (ANS) assay based on
previous studies [182]. Different concentrations (0.017, 0.02, 0.025, 0.033 and 0.05 mg/mL) of
samples were diluted in phosphate buffer (0.2 M, pH 7.5). ANS solution was prepared by
dissolving 8.0 mM ANS in 10 mM PBS (pH 7.0). Then 20 μL of prepared ANS solution was added
to 4 mL diluted sample solution, mixed and incubated for 15 min. Fluorescence intensity was
measured using S55 Fluorescence Spectrofluorometer (PerkinElmer, Waltham, MA, USA) at an
excitation wavelength of 390 nm and emission wavelength of 470 nm (both with a slit width 5 nm).
The initial slope of fluorescence intensity vs. sample concentration plot calculated by linear
regression analysis was used as an index of the surface hydrophobicity. Each sample was
calculated from at least three measurements.
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5.2.6. Drying and redispersion
All SLPN samples were spray dried by Nano Spray Dryer B-90 (Büchi Labortechnik AG,
Flawil, Switzerland). Nano spray drying was performed under following conditions: 100 °C inlet
temperature, 120 L/min flow rate, and 5.5 μm mesh size. The obtained sample powders were
checked for redispersibility by dissolving powders in water at a concentration of 1 mg/mL and
heating at melting point of corresponding solid lipid for 5 min was applied to achieve better
redispersibility. The particle size, PDI, and zeta potential were measured by DLS technique.

5.2.7. Morphological observation
SEM (JSM-6335F, JEOL Ltd., Tokyo, Japan) was conducted to visualize the morphology
and shape of liquid and spray dried powder samples. For liquid samples, a few drops of sample
were cast-dried on an aluminum pan overnight and then placed on the double-sided carbon tape
pre-affixed on a specimen stub. For powder samples, sample was directly placed on double-sided
carbon tape pre-affixed on a specimen stub. TEM (Tecnai T12, FEI, Hillsboro, Oregon, USA) was
used to observe the morphology of prepared curcumin-loaded SLPN. Samples were mixed with
equal volume of 2% phosphotungstate (pH 7) for 30 s. Then, one drop of stained sample was
placed on a copper grid for 10 min, followed by air drying for 10 s at room temperature before
loading onto TEM for observation.

5.2.8. Controlled release study
Kinetic release profiles of curcumin from SLPN were studied by dialysis tubing diffusion
method used in previous studies [104]. The release study was performed in SGF (pH 2) and SIF
(pH 7.5) with 50% (v/v) ethanol to create sink condition. Briefly, 3 mL of free curcumin (control) or
SLPN was sealed in a dialysis bag (molecular weight cutoff was 10–12 kDa) and immersed in
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60 mL of release medium in a sealed centrifuge tube. A 2-h SGF stage was followed by 4-h SIF
stage, and both stages were conducted in a water bath shaker with temperature at 37 ± 2 °C. At
each predetermined time interval, 1 mL of release medium was withdrawn and fresh medium was
replenished to keep the constant volume. The amount of curcumin in the withdrawn release
medium was determined by UV/Vis spectroscopy. Each release experiment was performed in
triplicate.

5.3. Results and discussion
5.3.1. Characteristics of SLPN prepared with different solid lipid
Six types of solid lipids, including two glyceride lipids and four fatty acids, were studied as
lipid core of SLPN (Fig. 5.1), namely, ATO888 mainly consisting of glyceryl dibehenate, ATO5
composed of glyceryl palmitostearate, BA (C22:0), SA (C18:0), PA (C16:0) and MA (C14:0). BD
conjugate was used as emulsifier to stabilize lipid core. According to our previous study, BSA
could be successfully conjugated with dextran and the grafting degree of such conjugate was
around 50% [183]. Our preliminary data suggested that BD conjugate alone cannot protect solid
lipid from precipitation under acidic condition, thus pectin was introduced to improve stability of
SLPN under low pHs. The structure and hydrocarbon chain length of solid lipid had significant
influence on the physicochemical characteristics of SLPN (Fig. 5.3). Generally, particle size of
SLPN was ranged from 210–370 nm, except those samples prepared with MA, which exhibited
dramatically greater particle size (714 nm). This might be attributed to the shorter hydrocarbon
chain of MA that resulted in relatively high hydrophilicity with a high water/oil partition coefficient,
leading to the formation of larger lipid droplets during homogenization. This explanation was also
evidenced by the fact that lipid nanoparticles prepared with BA (the longest hydrocarbon chain)
had a smaller particle size than those prepared with SA and PA which had shorter hydrocarbon
chain. In contrast, the particle size of SLPN prepared with two glyceride solid lipids (ATO888 and
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ATO5) was significantly smaller than those prepared with fatty acids (BA, SA, and PA). While
glyceryl dibehenate and distearate are known as the predominant fraction in ATO888 and ATO5,
respectively, both glyceride lipids contain several other lipidic components, such as mono- and
tri-esters. The multiple lipidic components are more beneficial for the formation of imperfect
crystallization structure in lipid core matrix, which would greatly reduce the size of droplets during
re-crystallization process [184, 185]. Compared with ATO5, ATO888 when used as lipid core
produced slightly smaller SLPN. The PDI of all groups was smaller than 0.3, which was indicative
of narrow size distribution of as-prepared SLPN, regardless of solid lipid type in the core. Zeta
potential is a critical factor to evaluate the stability of colloidal system. The zeta potential of SLPN
was in the range of −38 to −27 mV.
Turbidity of a colloidal sample is highly dependent upon the particle size and thus could
be indirectly used to estimate and compare particle size [186]. Generally speaking, a colloidal
sample with smaller particles does not scatter light as strongly as a sample containing larger
particles and thus is less turbid [187]. The turbidity results and digital photos of SLPN are shown
in Fig. 5.3A and B, which well agreed with particle size results determined by DLS. The SLPN
prepared with ATO888 exhibited the lowest turbidity and a translucent appearance, followed by
the one prepared with ATO5 and then BA, SA, PA and MA.

5.3.2. GI stability of SLPN
Generally speaking, SLPN prepared with two glyceride lipids and BA exhibited better GI
stability than other SLPN prepared with shorter hydrocarbon chain fatty acids (Fig. 5.3). For
ATO888-, ATO5-, and BA-SLPN, the fed-state gastric condition at pH 4 did not alter particle size
much, as the electrostatic interactions between BSA and pectin were well maintained at mild
acidic condition. In contrast, slight increase in particle size was observed when SLPN were
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incubated in simulated fasting-state gastric fluid at pH 2. This is, in part, attributed to the
protonation of carboxyl groups on pectin coating, which weakened the electrostatic interactions
between pectin and BSA. Thus, the polymeric network became loosen leading to the increase of
hydrodynamic diameter of SLPN. Nevertheless, it is notable that the effect of SIF at pH 7 on the
particle size varied with the lipid matrix. For SLPN prepared with two glyceride lipids, particle size
was slightly decreased, while interestingly, particle size remained the same for SLPN prepared
with BA, and significant increase in particle size was noted for SLPN prepared with shorter chain
fatty acids, i.e. SA, PA and MA. Discrepant effects of SIF on the particle size of lipid nanoparticles
have been previously reported, when different lipid matrix and emulsifiers were used in the
formulation [16, 130, 131, 188]. Although the underlying mechanism is not clearly understood yet,
several factors, including hydrophobicity of lipid matrix, amphiphilicity of emulsifiers, as well as
the interactions between lipid and emulsifiers, may collectively play important roles in the overall
stability of SLPN under simulated intestinal condition. In our previous studies, we demonstrated
that GI stable SLPN could be fabricated with use of either organic solvent [183] or chemical crosslinkers [14]. The results suggested that GI tract stable SLPN were obtained through this organic
solvent- and crosslinker-free preparation method.

5.3.3. Surface hydrophobicity of SLPN
A Fluorescence probe such as ANS has been successfully applied to determine the
surface hydrophobicity of proteins such as BSA [189], soybean protein [182], and whey protein
[190]. The ANS probe has low fluorescence intensity in aqueous solution, while after binding with
accessible hydrophobic regions of biomacromolecule, its fluorescence intensity significantly
increases and the intensity level is associated with the degree of hydrophobicity. In our study, the
ANS probe was applied to determine the effects of lipid matrix, pH adjustment and heating on
surface hydrophobicity of SLPN (Fig. 5.4). Surface hydrophobicity of initial SLPN prepared with
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different solid lipids, decreased in the following order: ATO888 < ATO5<BA < SA=PA=MA, which
agreed well with the intrinsic properties of each solid lipid. The treatment of pH adjustment and
heating significantly reduced surface hydrophobicity of SLPN prepared ATO888, ATO5 and BA,
while negligible effect was observed for SLPN prepared with SA, PA and MA, which showed
limited initial surface hydrophobicity. After pH adjustment to pI of BSA and heating, the protein
moiety on BD partially denatured and exposed more hydrophobic residues, thus facilitating strong
hydrophobic interactions with solid lipid matrix. This, in turn, reduced particle size by forming more
compact nanostructure, and the surface of SLPN became more hydrophilic, explaining the
reduced surface hydrophobicity. Several studies also found that pH adjustment and heating would
decrease surface hydrophobicity of proteins[191, 192]. In the meantime, under pH 4.7, negatively
charged and hydrophilic pectin was tightly adsorbed onto the surface of lipid nanoparticles
covered with positively charged BD conjugates, which could further decrease surface
hydrophobicity of nanoparticles. The results demonstrated that lipid nanoparticles have been
successfully coated with pectin and the hydrophilicity of SLPN has been significantly improved,
contributing to their exceptional colloidal stability in aqueous environment.

5.3.4. Morphological observation
The morphology of freshly prepared SLPN samples was observed by SEM and the results
are shown in Fig. 5.5. All SLPN exhibited solid structure with spherical shape except MA group,
which had amorphous structure and aggregated morphology. Overall, the particle size of SLPN
from SEM observation was larger than the hydrodynamic dimension measured with DLS, which
might be due to slow water removal rate through air-drying, causing fusion and aggregation of
lipid matrix. It is noteworthy that the trend in particle size change was in good agreement with the
results obtained with DLS measurement. In addition, the morphology of organic solvent-free
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pectin-coated SLPN in the present study was comparable with SLPN prepared with organic
solvent in our previous study [183].

5.3.5. Drying and redispersion of SLPN
Nano spray drying technology was applied to transform colloidal SLPN samples into dry
powders. The SEM images in Fig. 5.6A–F indicated that appreciable differences were found in
the morphology of powders prepared with different solid lipids. SLPN powders obtained from
ATO888 and ATO5 groups had most spherical shape, distinct and well-separated appearance
with the diameters ranging from 0.5 to 1.5 μm, while the powders from BA-, SA-, MA-, and PASLPN had sticky and heterogeneous morphology with diameters ranging from 0.5 to 4 μm. Large
aggregates and strong heterogeneity in size distribution of dried particles were appreciably
observed in PA- and MA-SLPN. This might be due to large amount of free lipids in these two
samples, due to the ineffective emulsification of short chain fatty acids. Previous studies have
reported that powders with significant aggregation were observed when drying lipid nanoparticles
without enough protection for the lipid core[142, 155]. During spray drying, the un-emulsified lipids
were heated up to 100 °C which was higher than the melting point of lipid, and thus free lipids
aggregated during re-crystallization when the temperature went down in the drying chamber
slowly [144].
The redispersibility of all SLPN dried powders was evaluated in water at concentration of
1 mg/mL without any emulsifiers or surfactants. All SLPN groups were able to redisperse upon
heating at melting point of corresponding solid lipid. The particulate characteristics and size
distribution curve of freshly prepared and redispersed samples are shown in Fig. 5.6a-e. ATO888-,
ATO5-, BA-SLPN were well redispersed in water after spray drying, although particle size
dramatically increased by 50–160 nm. The PDI of these three samples were maintained as the
same compared with initial PDI values. Once the hydrocarbon chain decreased to sixteen (C16),
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the redispersibility of SLPN powders was deteriorated. In particular, the redispersed SA-SLPN
showed a small peak at 7–8 μm with significantly increased PDI, indicating the existence of large
aggregates with a heterogeneous distribution. Although PA- and MA-SLPN groups exhibited nonsignificant increased and even reduced particle size compared to their colloidal states,
respectively, both samples showed 3-fold increase in PDI value, revealing the formation of
significantly aggregated particles during re-hydration. This was also reflected by the two peaks
on redispersed size distribution curve of PA- and MA-SLPN. These observations collectively
suggested that a large proportion of lipid matrix in these two samples remained as free bulky lipids
instead of nanoparticles. This assumption was well corroborated with their morphology observed
under SEM as discussed earlier. Our results demonstrated that although ATO888-, ATO5-, BAand SA-SLPN may agglomerate into bigger particles during spray drying, the polymeric outer
layers enabled them to redisperse and re-arrange into nanoscale particles in water during heating
and subsequent cooling process. Such redispersing and re-assembly phenomena have also been
reported in our previous studies (Wang et al., 2016a; Wang et al., 2017a).

5.3.6. Encapsulation and delivery potential of lipid nanoparticles
As one of the most studied lipophilic model compounds for designing a delivery system,
curcumin was used to investigate encapsulation capability of SLPN. In previous studies, the pHdriven process has been successfully applied to encapsulate hydrophobic compounds such as
curcumin, without use of organic solvent [79, 104]. In the present study, the process is based on
the deprotonation and dissolving of curcumin in BD conjugate solution at pH 12, followed by reassembly of BD micelles and simultaneous encapsulation of precipitated curcumin during
subsequent neutralization to pH 7.
SLPN with curcumin loading at 2.5%, 5%, and 7.5% (w/w, curcumin/lipid) were
successfully prepared. The particulate characteristics of curcumin-loaded SLPN are shown in Fig.
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5.7A–B (for 5% loading) and Fig. 5.8 (for 2.5% and 7.5% loading). Compared to unloaded SLPN,
the particle size and PDI of curcumin-loaded SLPN (at 2.5% and 5% loading) slightly increased
while zeta potential was relatively stable at different curcumin loading (data not shown).
Nevertheless, when curcumin loading reached 7.5%, SLPN became heterogeneous as particle
size and PDI both significantly increased compared to 2.5% and 5% groups, indicating that SLPN
may not be capable of encapsulating such high amount of curcumin.
The stability of curcumin-loaded SLPN in simulated GI conditions was investigated and
the results are presented in Fig. 5.7A–B (for 5% loading) and Fig. 5.8 (for 2.5% and 7.5% loading).
No significant changes were detected under simulated gastric and intestinal conditions, except
for MA-SLPN which exhibited rather poor GI stability with appreciable increase of particle size up
to 850 nm. Such tremendous increase in particle size might be due to the hydrophilic nature of
myristic acid, rendering its sensitivity to harsh conditions. Based on particulate and GI stability
results, the 5% loading group was chosen for further study.
The effects of solid lipids on encapsulation efficiency were investigated and the results are
shown in Fig. 5.7C. The encapsulation efficiency was in the range between 39% and 82%. SLPN
prepared with glyceryl lipids (ATO888 and ATO5) exhibited higher encapsulation efficiency than
fatty acids groups. This could be in part attributed to the formation of imperfect crystal framework
in the lipid core, since ATO888 and ATO5 have complex lipids which contain mixtures of mono-,
di-, and triglycerides. Several studies also found that preparing lipid nanoparticles with multiple
solid lipids increased encapsulation efficiency [193]. Besides, an increase of hydrocarbon chain
length of fatty acid is associated with elevated hydrophobicity of lipid matrix in the core of SLPN,
leading to higher accommodation of lipophilic payload.
Fluorescence spectroscopy was used to investigate binding capacity of curcumin to
hydrophobic molecules (Fig. 5.7D). The free curcumin, which was first dissolved in ethanol and
then diluted with water showed a broad peak at 549 nm. Curcumin in SLPN prepared with ATO888
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and ATO5 exhibited a strong peak at 505 nm, although curcumin encapsulated in SLPN prepared
with BA and SA exhibited slightly reduced fluorescence intensity with a further blue shift of its
peak to 495 nm. Collectively, compared to free curcumin, the blue shift and reduced intensity of
its maximum emission peak indicated a reduction in polarity in the microenvironment of curcumin
molecules, from polar aqueous-ethanol phase to hydrophobic lipid core of SLPN. However,
curcumin in SLPN prepared with PA and MA produced one peak and one shoulder: 463 and
490 nm for PA group, and 465 and 489 nm for MA group. The co-existence of peak and shoulder
in curcumin fluorescence emission suggested that the polarity of microenvironment in PA- and
MA-SPLN was significantly different than that in the SLPN samples prepared with other solid lipids,
revealing the effects of hydrocarbon chain [194]. Based on the results of particle size, PDI, GI
stability, and encapsulation efficiency, ATO888- and ATO5-SLPN showed superior properties to
various fatty acid groups. Although BA-SLPN showed the best results among fatty acid-SLPN,
the preparation temperature of BA-SLPN was too high (85 °C) that could possibly induce
degradation of curcumin. Therefore, SA-SLPN as a representative of fatty acid groups, as well as
ATO888- and ATO5-SLPN, were selected for morphology and release studies.
The morphology of curcumin-loaded SLPN prepared with ATO888, ATO5 and SA as lipid
core is shown in Fig. 5.9. All groups exhibited spherical shape and smooth surface, and the
observed size was smaller than the particle size measured by DLS. This inconsistency has been
commonly reported between TEM and DLS measurements, which is in part due to the factors
related to the high vacuum conditions of TEM, as well as the hydrodynamic and electrokinetic
effects in DLS [195, 196]. Some recent studies on solid lipid nanoparticles have also observed
smaller particles by TEM than DLS measurement [14, 197]. Comparatively, SLPN prepared with
ATO888 (Fig. 5.9A) exhibited the most homogeneous size distribution compared with those
prepared with ATO5 (Fig. 5.9B) and SA (Fig. 5.9C).
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The release kinetics of curcumin from SLPN were investigated in SGF (pH 2, 2 h) and SIF
(pH 7, 4 h) consecutively to simulate in vivo digestive condition. The release profiles are shown
in Fig. 5.10. The diffusion rate of free curcumin was much faster than encapsulated curcumin,
with about 60% and 80% of curcumin detected in the release medium at the end of SGF and SIF
stage, respectively. Three SLPN samples exhibited considerable different release profile, with
cumulative curcumin released after 6 h incubation being 40%, 50%, and 56% for ATO888-, ATO5,
and SA-SLPN, respectively. Apparently, better retention of curcumin was achieved by SLPN
prepared with glycerides (ATO888 and ATO5) than the one prepared with long chain fatty acid
(SA), resulting in the higher release rate for SA-SLPN. The lower melting point of ATO5 (50–60 °C)
may lead to a higher mobility during release procedure, explaining a slightly faster release. Our
results clearly suggested that the as-prepared SLPN effectively improved the stability and release
profile of curcumin in simulated GI condition, indicating their promising potential for oral delivery.

5.4. Conclusion
In this study, an innovative oral delivery system, SLPN, was prepared from all-natural
biomaterials without use of synthetic surfactants, toxic chemicals, or organic solvents. Six types
of solid lipids, including two glycerides and four saturated fatty acids, were comprehensively
tested for their applicability to prepare SLN core and their compatibility with polymeric shells to
form SLPN. SLPN prepared with glycerides exhibited superior colloidal properties, including
smaller particle size, narrower size distribution, and better stability under simulated GI fluids,
compared to those prepared with fatty acids. Hydrophobic interactions were the driving force to
form SLPN with BD conjugate, while pectin coating afforded greater surface hydrophilicity
responsible for exceptional colloidal stability under GI conditions. SLPN demonstrated high
encapsulation efficiency and controlled release of curcumin, with glycerides as lipid core was
more desirable than those prepared with fatty acids. Collectively, this study provides a promising
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strategy to develop safe and effective oral delivery platform for lipophilic bioactives, which may
open new avenues in functional foods.
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5.5. Figures and tables
Figure 5.1 Chemical structure of solid lipids used in the preparation of SLPN.
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Figure 5.2 (A) Schematic representation of the Maillard conjugation. This figure shows the
formation of the Amadori products. (B) Schematic diagram of fabrication of pectin-coated SLPN.
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Figure 5.3 Turbidity (A) and digital photos (B) of SLPN with pectin layer prepared with different
solid lipid. Stability of SLPN with pectin (C–D) in simulated GI conditions. PS: particle size.
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Figure 5.4 Surface hydrophobicity of SLPN (without encapsulation of curcumin) before and after
pH adjustment and thermal treatment.
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Figure 5.5 SEM images of cast-dried SLPN (with pectin) samples prepared with ATO888 (A),
ATO5 (B), BA (C), SA (D), PA (E), and MA (F).
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Figure 5.6 SEM images of spray-dried SLPN (with pectin) samples prepared with ATO888 (A),
ATO5 (B), BA (C), SA (D), PA (E), and MA (F). Redispersed spray dried sample of SLPN
prepared with ATO888 (a), ATO5 (b), BA (c), SA (d), PA (e), and MA (f). The statistical
difference in particle size and PDI data was respectively noted with superscript letter between
original and redispersed samples (P < 0.05).
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Figure 5.7 (A) Stability of 5% (w/w, curcumin/lipid) curcumin loaded SLPN (A–B) in simulated GI
conditions; (B) Encapsulation efficiency of curcumin loaded SLPN prepared with different solid
lipid. The statistical difference was noted with upperletters among samples; (D) Fluorescence
emission spectra of free curcumin and curcumin-loaded SLPN. All original SLPN samples had
the same pH 4.7, as they were adjusted before heating treatment during sample preparation.
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Figure 5.8 Stability of 2.5% (A-B) and 7.5% (C-D) (w/w, curcumin/lipid) curcumin loaded SLPN
under simulated GI conditions.
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Figure 5.9 TEM images of 5% curcumin-loaded ATO888-SLPN (A), ATO5-SLPN (B) and SASLPN (C).
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Figure 5.10 In vitro release profile of curcumin from SLPN prepared with different solid lipid and
free curcumin control.
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Chapter 6 Study 4
Solid lipid–polymer hybrid nanoparticles by in
situ conjugation for oral delivery of astaxanthin

This study has been published in Journal of Agricultural and Food Chemistry, 2018, 66, 94739480. This chapter was adapted and reprinted with permission from American Chemical
Society.
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6.1. Background
To simultaneously achieve desirable GI stability and maintain food-grade, we have
designed a series of SLPN formulations using natural biopolymers as food-grade emulsifiers and
stabilizers during preparation in previous studies [14, 183]. In particular, the Maillard conjugates
of BSA and dextran were tested in our previous study to fabricate highly stable SLPN suitable for
oral delivery. Although the Maillard conjugate was found to be effective, pectin coating was
needed to stabilize SLPN in gastric condition. Pectin coating, however, significantly increased the
particle size from 150 nm to 250–300 nm, which may affect delivery efficacy.
Therefore, in this study, we aimed to develop a novel strategy that can not only maintain
the small size of SLPN but also achieve exceptional GI-stability. To accomplish this goal, dextran
was first functionalized by oxidation through sodium periodate, and the resultant oxidized dextran
(Ox-Dex) having multiple aldehyde groups is capable of forming covalent bond (imine bond or
Schiff base) with polymers containing amino groups, i.e., BSA, under mild reaction condition. We
hypothesized that SLPN could be prepared using BSA as a natural emulsifier and then Ox-Dex
could act as a macromolecular cross-linker to covalently bind with the BSA layer to further stabilize
the enveloped SLN in the core, forming stable SLPN. This process is therein referred to as in situ
conjugation as the covalent bond is spontaneously formed during heating step within SLPN
preparation. The physicochemical properties of the obtained SLPN, including particulate
characteristics, colloidal stability, and morphology, were comprehensively characterized. ASTN,
a keto-carotenoid, was studied as a lipophilic model compound to explore the encapsulation and
delivery potential of SLPN.

6.2. Experimental design
6.2.1. Preparation and characterization of Ox-Dex
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Ox-Dex was synthesized according to previous literature with some modifications [198].
Dextran with molecular weights 20, 40, 75, and 150 kDa were used to prepare Ox-Dex, and the
oxidation procedure was carried out in a beaker protected from light. Briefly, native dextran
solution (2.4 g/50 mL) was treated with 0.2 M NaIO4 (50 mL) for 24 h at room temperature at pH
4. The mixture was then dialyzed against purified water for 24 h, followed by freeze-drying for 48
h.
The substitution degree of dextran was measured by titration method [199]. Briefly, 100
mg of Ox-Dex powder was precisely weighed and dissolved in 25 mL of 0.25 M hydroxylamine
hydrochloride solution. The obtained solution was stirred for 2 h in the dark at room temperature
for the reaction to complete. Then, the mixture was titrated with standardized 0.1 M NaOH solution.
The substitution degree of Ox-Dex was calculated by the following equation:

Substitution degree (%) =

Mol of CHO (VNaOH ×NNaOH )×10-3
×
100%
Mol of dextran WOx-Dex /MWDextran

where VNaOH is the volume of NaOH solution used for titration (mL), NNaOH is the NaOH
concentration (mol/L), WOx–Dex is the weight of Ox-Dex sample used (g), and MW Dextran is molecular
weight of dextran used for oxidation.
Both FTIR and nuclear magnetic resonance spectroscopy (NMR) were used to confirm
the existence of aldehyde groups after oxidation. For FTIR spectrum analysis, freeze-dried OxDex was mounted into ATR crystal for measurement using a Nicolet iS5 FTIR spectrometer
(Thermo Scientific, Waltham, MA, U.S.A.). The spectra were collected from the wavenumber of
500–4000 cm–1 at a resolution of 4 cm–1. For NMR, 1H spectra of native dextran and Ox-Dex
(dissolved in D2O at concentration of 10 mg/mL) were acquired on an AVANCE 300 MHz NMR
spectrometer.
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6.2.2. Preparation of SLPN with Ox-Dex and BSA
SLPN were prepared through an organic solvent-free homogenization and sonication
technique as described in our previous study [181]. Briefly, 10 mg of Precirol ATO 5 powder was
heated to melt at 65 °C. Then, 10 mL of preheated (65 °C) water phase, containing 1 mg/mL BSA
and 1 mg/mL Ox-Dex solution, was mixed with melted lipid under homogenization at 25 000 rpm
for 30 s to obtain coarse emulsion, followed by 3 min sonication by a probe-type sonicator (Misonix
Sonicator 3000, U.S.A.). Then, samples were incubated under 65 °C, 75 °C, or 85 °C for 30, 60,
and 120 min to initiate the conjugation reaction between BSA and Ox-Dex, forming Schiff-based
complexes. After heating, samples were rapidly cooled down in ice bath to solidify the solid lipid
core. As a control, SLPN composed of native dextran were prepared similarly but using native
dextran instead of Ox-Dex.
To encapsulate ASTN into SLPN, ASTN was first dissolved in acetone at a concentration
of 0.2 mg/mL. Then, 1 mL of ASTN solution and solid lipid were mixed and incubated together at
65 °C. Then, the same fabrication procedures were followed as mentioned above.

6.2.3. Characterization of SLPN
Particle size and PDI of SLPN were measured by DLS using Zetasizer Nano ZS at 25 °C
(Malvern Instruments Ltd., Worcestershire, U.K.). Zeta potential was measured using
electrophoresis technique by the same instrument. Samples were diluted 10 times with buffer
solution (same pH as samples) to avoid multiple scattering.
The GI stability of the SLPN samples was determined according to the method in our
previous study [14]. Briefly, 1 mL of SLPN sample was mixed with 9 mL of SGF (pH 2 with 1
mg/mL pepsin) and incubated at 37 °C for 2 h. After SGF stage, 1 mL of above mixture was added
into 9 mL of SIF (pH 7 with 10 mg/mL pancreatin) and incubated at 37 °C for another 4 h. The
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pepsin and pancreatin were dissolved in SGF and SIF overnight respectively under 4 °C. Both
SGF and SIF were filtered through 0.45 μm membrane to remove any impurities before use. At
the end point of each incubation, particle size and PDI of SLPN were measured by DLS as
previously described.

6.2.4. Determination of encapsulation efficiency
EE of ASTN-loaded SLPN was determined by measuring the concentration of free ASTN
using extraction method. Briefly, 1 mL of freshly prepared ASTN-loaded SLPN was freeze-dried,
and then 5 mL of acetone was added to extract the free ASTN from obtained SLPN powder. The
concentration of ASTN in acetone was analyzed by a UV/vis spectroscopy at 480 nm, with a preestablished ASTN standard curve. The EE of ASTN-loaded SLPN was calculated using following
equation:

EE (%) =

MT -Mfree
× 100%
MT

where MT is the total mass of ASTN added during SLPN fabrication, and Mfree is the mass of free
ASTN in the extract.

6.2.5. Spray drying process
The SLPN samples were spray dried by a Nano Spray Dryer B-90 (Büchi Labortechnik
AG, Flawil, Switzerland). The spray drying conditions were as follows: inlet temperature at 100 °C,
flow rate at 120 L/min, and mesh size of 4 μm.

6.2.6. Morphological observation
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The morphology of freshly prepared colloidal SLPN was observed using a TEM (FEI,
Tecnai 12 G2, Spirit, BioTWIN, Netherlands). Before observation, 3 μL of each diluted sample (6
times dilution, 0.5 mg/mL) was deposited on a plasma cleaned carbon-coated grid for 2 min. The
grid was rinsed off by 100 μL of 0.5% uranyl acetate stain solution and air-dried completely. The
morphology of spray dried SLPN sample was analyzed using a SEM (JSM-6335F, JEOL Ltd.,
Tokyo, Japan) at an accelerated voltage of 10 kV. Spray-dried powder samples were directly
placed on double-sided carbon tape preaffixed on a specimen stub and coated with gold layer by
a sputter coater before observation under SEM.

6.2.7. ABTS radical scavenging assay
ABTS assay was performed to determine the antioxidant activity and the detailed protocol
was described in our previous study [87]. The antioxidant activity was expressed as mg vitamin
C equivalent antioxidant capacity per micro liter sample. The ASTN-loaded SLPN and free ASTN
were tested at equivalent ASTN concentrations in a wide range, i.e., 0.25, 0.5, 2.5, 5, and 10
μg/mL. Free ASTN was dissolved in acetone at 0.5 mg/mL and then diluted with water to the
appropriate concentration.

6.2.8. In Vitro controlled release study
The in vitro release of ASTN from SLPN was conducted using the dialysis method reported
by previous study [14]. The free ASTN or ASTN-loaded SLPN was placed in a dialysis bag, and
both sides of the bag were clipped and sealed. The bag was first placed into SGF (pH 2 with 0.5%
v/v Tween 80, 37 °C) for 2 h and then transferred into SIF (pH 7 with 0.5% v/v Tween 80, 37 °C)
for another 4 h. The release system was carefully sealed to prevent evaporation. During the
experiment, 2 mL of release medium were withdrawn at predetermined time intervals (every 15
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and 30 min for SGF and SIF stage, respectively) with the replacement of the same volume of
fresh medium. The collected release medium at each time point was then lyophilized for 24 h.
After that, the released ASTN was extracted by 3 mL of acetone. The amount of released ASTN
was determined by UV/vis spectroscopy at 480 nm using an ASTN standard curve.

6.3. Results and discussions
6.3.1. Characterization of oxidized dextran
Native dextran was oxidized with sodium periodate (NaIO4). During the oxidation process,
the periodate ion attacks one of the hydroxyl groups (between C2–C3 or C3–C4) of dextran,
resulting in a breakage of the C–C bond, yielding two aldehyde groups (Fig. 6.1A). Since the
aldehyde group in C3 position has a vicinal hydroxyl group which is susceptible for further
oxidation, it will undergo second oxidation and form a dialdehyde group [200-202]. The oxidation
degree of Ox-Dex was determined by hydroxylamine method, and the results are displayed in
Table 6.1. The number of aldehydes in native dextran and Ox-Dex was calculated and compared.
The degree of oxidation was 21.7, 28.1, 25.2, and 25.3% for 20, 40, 75, and 150 kDa dextran,
respectively. To confirm the oxidation reaction of dextran, the Ox-Dex (40 kDa) was analyzed by
FTIR (Fig. 7.1B) and NMR (Fig. 7.1C) spectroscopy. In FTIR spectrum, the dialdehyde absorption
peak (1730 cm–1) which is associated with the C═O group was detected in Ox-Dex [200]. In the
1H NMR spectra of native dextran and Ox-Dex, there were peaks between δ 3.0–5.0 ppm which
were assigned to the protons at six carbons in the glucose unit. The spectra of Ox-Dex exhibited
several distinctive peaks in the range of 4.2–5.8 ppm, which were assigned to the protons from
different hemiacetal structures [202, 203]. These results confirmed that oxidation of dextran was
successful and dialdehyde groups were formed in the dextran chain.
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6.3.2. Characterization and optimization of SLPN
In our previous study, GI-stable SLPN were successfully prepared with BSA-dextran
Maillard conjugate as a natural macromolecular emulsifier and pectin coating as a stabilizer [183].
In that study, we proved that BSA-dextran conjugate alone was unable to provide sufficient
stabilization against aggregation under gastric conditions. Although pectin coating covering the
surface of BSA-dextran emulsified SLN conferred satisfactory stability, the chemical nature of
pectin limited further modification on its surface to fine-tune nanoparticles functionality, such as
associating with ligand for target delivery. Therefore, in the current study, an attempt was made
to design a novel GI-stable formulation of SLPN without using pectin coating, and simultaneously
plenty of aldehyde functional groups were introduced on the nanoparticle surface via in situ
conjugation between Ox-Dex and BSA. A detailed preparation procedure is illustrated in Fig. 6.2.
Initially, native dextran was attempted in this design, as it also contains a few aldehyde groups in
its open-chain structure, although very few, which may also cross-link with amino groups in BSA.
Nevertheless, even though SLPN with small particle size and homogeneous distribution could be
successfully prepared with native dextran, the GI-stability of obtained SLPN was very poor that
they precipitated instantly when incubating in simulated gastric fluid, due to weak and limited
conjugation degree between native dextran and BSA (Fig. 6.3).
To investigate the optimal conjugation conditions between BSA and Ox-Dex, effects of
four types of Ox-Dex prepared from dextran with different molecular weights (20, 40, 75, and 150
kDa), three different heating temperatures (65 °C, 75 °C, and 85 °C), and three different heating
durations (30, 60, and 120 min) on the particulate characteristics were explored. Particulate
characteristics including particle size, PDI, and count rate were measured, and the data were
analyzed with the statistical significance at α = 0.05 by variance analysis. Count rate is defined
as the number of photons detected per second by the DLS instrument, which is often considered
as an indicator of the nanoparticle concentration and formation. The standardized Pareto chart
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for the three factors is presented in Fig. 6.4, where a large effect indicates strong influences and
a reference line was drawn to elucidate the statistical significance. It is notable that no association
between molecular weight of dextran and particulate characteristics of SLPN, including particle
size (p = 0.78), PDI (p = 0.76), and count rate (p = 0.57). The mean particle size, PDI, and count
rate of SLPN prepared using Ox-Dex with different molecular weight was found to be similar,
around 158 nm, 0.199, and 358.2 kcps, respectively (Fig. 6.5). Clearly, there is no evidence that
low or high molecular weight of dextran could help produce SLPN with the best characteristics
(smallest particle size and PDI, highest count rate). Nevertheless, SLPN prepared with 40 kDa
Ox-Dex showed overall slightly superior properties with relatively small particle size, smallest PDI,
and highest count rate. Therefore, SLPN prepared with 40 kDa Ox-Dex was selected in further
studies. The information on particulate characteristics and GI-stability of SLPN prepared with 20,
75, and 150 kDa Ox-Dex can be found in Fig. 6.6-6.9.
From Fig. 6.10, it is clear that the characteristics of SLPN prepared with 40 kDa Ox-Dex,
including particle size, PDI, and count rate, are mostly determined by the temperature and
duration of heating and their interactions. In particular, as shown in Fig. 6.10A1 and A2, the
particle size significantly increased from 150 to 800 nm by increasing the heating temperature.
Unlike conventional bifunctional reagents (e.g., GA) which are known to create intermolecular
conjugation among protein molecules, Ox-Dex could instead rapidly cover the surface of BSA
molecules and thus avoid inter-protein reactions during conjugation procedure [204]. Thus, higher
conjugation efficiency at elevated temperature may lead to thicker Ox-Dex layer covering the
surface of SLPN, resulting in larger particle size. Meanwhile, the interaction between heating
temperature and time had a significant impact on particle size. When the heating temperature
was equal to or higher than 75 °C, greater particle size was observed as the increase of heating
time. In contrast, the effect of heating time on particle size was negligible when the heating
temperature was 65 °C. This observation revealed that the optimal combination of heating time
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and temperature is required to achieve a high conjugation degree while maintaining the original
particle size. Our results were corroborated with previous literature that the reaction conditions
(e.g., temperature, incubation times) could strongly influence the properties of final product
produced by cross-linking between aldehydes and proteins [205, 206]. Notably, aggregation of
SLPN (particle size >1000 nm) was observed if being heated at 85 °C for extended time, i.e., 60
and 120 min. Such precipitation of SLPN may be attributed to the loss of emulsification capability
of BSA due to excessive conjugation and thermal denaturation under these two conditions [207].
The effects of heating temperature and time on PDI of SLPN are shown in Fig. 6.10B1 and B2.
Generally, the PDI ranged from 0.11 to 0.23 under various preparation conditions, suggesting that
under the studied preparation conditions all SLPN samples had a narrow distribution of particle
size. The Pareto chart in Fig. 6.4B indicated that heating temperature, duration, and their
interaction had remarkable influence on the PDI values, while such influence was not noted until
the temperature reached 75 °C. In particular, heating temperature played a predominant role, and
the lowest PDI was observed when SLPN was heated at 85 °C for 30 min. Nevertheless, if SLPN
were heated at 85 °C for more than 30 min, then the theoretical PDI would have soared from 0.15
to 0.5–0.7, based on contour plot (Fig. 6.10B2). Smaller PDI of SLPN could be ascribed to the
formation of more homogeneous Ox-Dex coating as the degree of conjugation increased. Since
the Schiff-base formation is a kinetic and thermodynamic process, Ox-Dex did not adsorb onto
and conjugate with BSA layer at the initial stage of heating. But as the reaction proceeded, more
Ox-Dex conjugated with BSA and less free Ox-Dex remained in the aqueous phase, and hence
a more ordered structure was formed, resulting in the formation of uniform coating layer and thus
the SLPN with narrow size distribution. As shown in Fig. 6.10C1 and C2, the count rate varied
from 295 to 475 kcps with different levels of variation. The count rate gradually and significantly
increased as the increase of both heating temperature and time. The significant augment in count
rate evidenced that more nanoparticles were formed during preparation when higher temperature
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and longer heating time were involved. Nevertheless, the count rate was significantly reduced
when SLPN was heated at 85 °C for 60 min or longer, which could be due to the precipitation.

6.3.3. GI stability
GI-stability is an important parameter for measuring the capability of SLPN as a potential
oral delivery system. The stability of SLPN in the GI tract was evaluated by incubating SLPN
samples in either simulated gastric condition (pH 2) with pepsin for 2 h or intestinal condition (pH
7) with pancreatin for 4 h. Generally speaking, SLPN prepared with higher temperature and longer
heating time exhibited better stability under both SGF and SIF conditions (Fig. 6.11). Comparing
the three SLPN prepared under 65 °C, their stability in gastric phase was more appreciably
affected by heating time, while such heating time-dependent effect was not noted in the intestinal
phase. However, once the heating temperature raised to 75 °C, the GI-stability was greatly
improved regardless of heating time. Apparently, with negligible changes in particle size and
maintaining smallest PDI throughout GI incubation, the SLPN prepared with heating at 85 °C for
30 min had the optimal GI stability among all samples.
To investigate whether heating time could be shortened when heated at high temperature,
SLPN were prepared by heating at 85 °C for 10 and 20 min. The initial particulate characteristics
and their GI-stability data are shown in Fig. 6.12. Although shorter heating time was favorable to
reduce particle size, these samples had significantly greater PDI values under SGF phase,
compared with the one prepared with 30 min heating. It turned out that 30 min heating time was
necessary to induce complete conjugation between BSA and Ox-Dex, otherwise the prepared
SLPN had poor GI-stability. This confirmed that heating at 85 °C for 30 min was the optimal
condition to prepare GI-stable SLPN, and thus this SLPN was selected in following studies.
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6.3.4. Morphological observation
The morphology of freshly liquid SLPN sample (heating at 85 °C for 30 min) was observed
using TEM (Fig. 6.13A). The SLPN had spherical shape and narrow size distribution ranging from
120–150 nm. Due to high vacuum condition in TEM and hydrodynamic and electrokinetic effects
in DLS [195, 196]. the observed particle size was smaller than the size measured by DLS. Fig.
6.13B illustrates a SEM image for the spray-dried SLPN sample obtained by nano spray drying
technology. These powders showed spherical particles with a wide distribution of size ranging
from 500 nm to 1.5 μm. The increased particle size may be attributed to agglomeration of multiple
nanoparticles during ultrasonic vibration and compression process of the mesh during spray
drying [14, 155]. According to previous studies, powders with significant aggregation could be
observed when spray-drying lipid nanoparticles without sufficient protection such as addition of
spacers or coating [142, 155]. Thus, the conjugation procedure between BSA and Ox-Dex
prevented solid lipid core from severe aggregation and helped SLPN to from spherical, distinct,
and separated particles during spray drying.

6.3.5. Encapsulation and delivery potential of ASTN
It is well-known that ASTN has a very poor solubility in water, but it is soluble in organic
solvents such as acetone, chloroform, and dimethyl sulfoxide (DMSO). Thus, in the current study,
ASTN was encapsulated into SLPN with the assistance of acetone. The ASTN-loaded SLPN (ASLPN) were successfully prepared with 70% encapsulation efficiency, which equaled 0.14 mg of
ASTN was encapsulated into the core of SLPN. The characteristics of ASTN-loaded SLPN are
shown in Fig. 6.14A. Compared to the empty SLPN vehicle, the particle size and PDI slightly
increased to 197 nm and 0.119 from 167 nm and 0.111, respectively. Encapsulation of ASTN did
not alter the GI-stability of SLPN, as no significant changes were detected for particle size and
PDI of ASTN-SLPN during incubation under simulated digestive conditions. As indicated in Fig.
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6.14B, the morphology of A-SLPN was consistent with the original SLPN, and the particle size
estimated from TEM image well matched with the DLS measurement.
Potent antioxidant activity is one of the health-promoting properties that distinguishes
ASTN from other carotenoids. Nevertheless, due to its poor water solubility, its antioxidant activity
is specifically limited to the lipid oxidation and so its health benefits may be limited in the aqueous
phase. Encapsulation of lipophilic bioactives into nanoscale vehicles that can disperse well in
aqueous conditions has been demonstrated as a promising strategy to tackle the challenge of
water solubility/dispersibility. The comparison of antioxidant activity between free ASTN and
encapsulated ASTN in SLPN (A-SLPN) is presented in Fig. 6.14C. It is apparent that at a wide
range of concentrations studied (0.25–10 μg/mL), A-SLPN exhibited significantly higher
antioxidant activity in the aqueous condition-based ABTS assay. Especially, A-SLPN had strong
activity at very low concentration (0.25 μg/mL), while free ASTN began to have similarly notable
activity at 10 μg/mL. Free ASTN cannot be well dissolved thus separated out in aqueous media,
resulting in limited contact probability with free radicals. However, SLPN with a hydrophobic lipid
core and hydrophilic coating not only provided nonpolar microenvironment for the encapsulated
ASTN but also improved its dispersion in aqueous condition to scavenge the hydrophilic free
radicals, such as ABTS [87].
The in vitro release profile of ASTN from A-SLPN was evaluated in SGF (pH 2, 2 h) and
SIF (pH 7, 4 h), consecutively (Fig. 6.14D). The free ASTN control group exhibited a triphasic
diffusion pattern, with an initial burst diffusion of about 50% within 1 h and then a slower rate for
remaining 1 h in SGF, followed by a slightly faster and constant diffusion rate in SIF. In contrast,
the A-SLPN showed a similar triphasic pattern but with a significantly slower rate, with only about
40 and 55% of ASTN detected in release medium after SGF and SIF stage, respectively. The
data for ASTN release from A-SLPN fitted well into the Higuchi model (R2 = 0.9434, y = −0.9795
+ 3.3353x), which indicated that the release of ASTN followed a matrix diffusion-based kinetic.
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6.4. Conclusion
In this study, Ox-Dex was first prepared by oxidizing native dextran to expose more
aldehyde groups. Then, the prepared Ox-Dex, together with BSA, was used to stabilize Precirol
ATO 5 (glyceryl distearate) to produce SLPN through an in-situ conjugation technique. The
formulations and preparation parameters during preparation procedure including molecular
weight of native dextran and conjugation temperature and time were comprehensively optimized.
High conjugation temperature (85 °C) and short incubation time (30 min) were found to be critical
in producing small, homogeneous, and GI stable SLPN. The optimized SLPN exhibited
significantly improved GI stability due the strong covalent bond between the aldehyde group of
Ox-Dex and the amino group of BSA. The optimized SLPN were later used to encapsulate ASTN
and they were able to offer a good capacity for ASTN with 70% encapsulation efficiency.
Encapsulation of ASTN in SLPN showed sustained release kinetics in simulated GI fluid
compared with free ASTN. Our study demonstrated that the SLPN coated with the covalently
bonded Ox-Dex-BSA layer holds promising potential as an oral delivery system for lipophilic
nutrients.
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6.5. Figures and tables
Figure 6.1 (A) The corresponding reaction of preparing oxidized dextran; (B) FTIR spectra of
native dextran and oxidized dextran (40 kDa); and (C) 1H NMR spectra of native dextran and
oxidized dextran (40 kDa).
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Figure 6.2 In situ conjugation process and formation of SLPN.
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Figure 6.3 Particle size (A) and PDI (B) of SLPN prepared with native dextran (40 kDa).
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Figure 6.4 Pareto chart of the standardized effects on different responses: (A) particle size, (B)
PDI, and (C) count rate.
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Figure 6.5 Main effect of particle size (A), PDI (B), and count rate (C) among dextran with
different molecular weight.
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Figure 6.6 Particle size (A1) and PDI (A2) of SLPN (20 kDa dextran used); Stability of SLPN in
simulated gastric (B1-2) and intestinal (C1-2) conditions.
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Figure 6.7 Particle size (A1) and PDI (A2) of SLPN (75 kDa dextran used); Stability of SLPN in
simulated gastric (B1-2) and intestinal (C1-2) conditions.
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Figure 6.8 Particle size (A1) and PDI (A2) of SLPN (150k Da dextran used); Stability of SLPN in
simulated gastric (B1-2) and intestinal (C1-2) conditions.
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Figure 6.9 Count rate of SLPN prepared with 20kDa (A), 75kDa (B), and 150kDa (C) Ox-Dex.
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Figure 6.10 Particle size (A1), PDI (B1), and count rate (C1) of SLPN (40 kDa dextran used);
contour plot illustrating the effect of significant factors (time and temperature) to particle size
(A2), PDI (B2), and count rate (C2). Under the same heating temperature, data not sharing the
same upper letter were significantly different.
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Figure 6.11 Stability of SLPN in simulated gastric (A) and intestinal (B) conditions. The “*”
indicates the statistical difference compared to the original value of particle size (Fig. 6.10A1)
and PDI (Fig. 6.10B1) for the same sample.
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Figure 6.12 Particle size (A), PDI (B), and count rate (C) of SLPN (40 kDa dextran used)
prepared under heating at 85 °C for different durations, as well as their respective stability in
SGF and SIF. In (A) and (B), the statistical differences between samples before (original) and
after incubation in SGF or SIF were indicated by “*”. While in (C), data not sharing the same
upper letter were significantly different.
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Figure 6.13 TEM (A) of freshly prepared SLPN sample. SEM (B) of spray-dried SLPN sample.
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Figure 6.14 (A) Particle size, PDI, and encapsulation efficiency (EE) of ASTN-loaded SLPN; (B)
TEM image of ASTA-loaded SLPN; (C) the ABTS radical scavenging activity of free and
encapsulated ASTN. (D) In vitro release profile of ASTA-loaded SLPN. In (C), at each
concentration of ASTN, data not sharing the same upper letter were significantly different.
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Table 6.1 Oxidation degree of Ox-Dex.
Molecular weight of
native dextran (kDa)
Oxidation degree (%)

20

40

75

150

21.7 ± 1.5 %

28.1 ± 2.1 %

25.2 ± 1.9 %

25.3 ± 1.7 %
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Chapter 7 Conclusion and Future Directions

Part of contents, including texts and figures, has been published in Nanoscale, 2019, 11, 1104811063. This chapter was adapted and reprinted with permission from Royal Society of
Chemistry.
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In this project, we first fabricated SLPN with polymeric DL coating (NaCas and pectin) by
utilizing hydrophobic and electrostatic interactions. To reinforce the DL structure and achieve
better GI stability, the obtained DL-SLPN were chemically cross-linked by GA or EDC/NHS. The
cross-linked SLPN exhibited excellent GI stability against simulated fed gastric and intestinal fluid
compared with non-cross-linked SLPN. However, the use of chemical cross-linkers (i.e. GA and
EDC/NHS) might pose toxicity problems for further applications for oral delivery of bioactive
compounds.
Thus, in the second and third study, we tried to develop a synthetic surfactant-free and
cross-linker-free method was developed to fabricate SLPN with natural biomaterials. In this study,
BSA and dextran were first conjugated through Maillard reaction to improve the resistance against
pH variation. The Maillard conjugates were then exploited to emulsify solid lipid to form
nanoparticles. Subsequently, the multilayer structure was formed by self-assembly of BSAdextran micelles to envelope solid lipid via a pH- and heating-induced facile process with
simultaneous surface deposition of pectin. The obtained SLPN showed excellent GI stability and
held great potential for the oral delivery of lipophilic bioactive compounds. Although the Maillard
conjugate was found to be effective, pectin coating was needed to stabilize SLPN in gastric
condition. Due to the additional layer of pectin, the particle size significantly increased from 150
nm to 250–300 nm, which may affect delivery efficacy. Besides, the fabrication process of Maillard
conjugates was complicated and time-consuming, and the composition of Maillard conjugates
was difficult to isolate and analyze.
Therefore, in the last study, we developed a more simple but effective SLPN formulation.
In the study, native dextran was first oxidized to expose more aldehyde groups. The prepared OxDex, together with BSA, was used to stabilize solid lipid to form nanoparticles. The stability of
BSA and the linkage between BSA and Ox-Dex was reinforced through in-situ conjugation
technique. During in-situ conjugation, the aldehyde groups of Ox-Dex was cross-linked with amino
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groups of BSA to form strong Schiff base. The optimized SLPN exhibited significantly improved
GI stability. Also, the SLPN offered a good capability to encapsulate model lipophilic bioactive
compound (i.e. ASTN) with 70% encapsulation efficiency. Encapsulation in SLPN significantly
decreased the release rate of ASTN compared with free ASTN.
Our study mainly focused on in vitro tests and most of the studies employ static models
that usually consist of dilute digestive mixture that mimics pH, minerals, ionic strength, and
enzymes in physiological conditions in human GI tract. Unfortunately, information generated from
such static models can hardly be related to in vivo conditions, since human GI tract is a complex
and dynamic system under physiological conditions. In future studies, it is critical to determine the
biological fate of lipid nanoparticles through oral administration using in vivo models, which would
give us useful guidance for evaluation of delivery efficacy of LN under physiological conditions.
Before such an approach could be pushed forward, plenty of work and research are required to
develop and validate the animal models and analytical methods available for assessing lipid
nanoparticles digestion and uptake. For instance, the fluorescence probes/markers should be
able to act as an effective indicator for nanoparticles. Since some of the fluorescence probes,
such as FITC, can still emit fluorescence after leakage, the fluorescence signals could not be
used as indicators for intact nanoparticles. Furthermore, although animal models are widely used
to predict human response to either lipid nanoparticles or encapsulated drugs/nutrients after oral
ingestion, most of the results that are found in animal models could not be reproduced in human
trials (clinical trials). Thus, in order to bridge the translational gaps between animal models and
humans, it is necessary to carry out human studies to investigate the in vivo biological fate of
orally administered lipid nanoparticles and encapsulated cargos. Such human studies will require
considerable work to develop and validate the study designs, as well as to ensure the reliability
of detecting and analytical techniques for lipid nanoparticles after administration. Future work may
focus on incorporation of drug/nutrient-loaded lipid nanoparticles into food matrix to prepare
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health supplements for enhanced absorption, bioavailability, and even treatment effects, which
may provide useful guidance with respect to lipid nanoparticles formulation design and
commercialization as pharmaceutics or nutraceuticals.
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